{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00016403", "CSN": null, "TRF": "ORD_1188306_01", "MRN": "46795442", "PhysicianId": "53741", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "886839", "clinicalId": "888244", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1188306_01", "SampleName": "US1148014.01", "Version": "0", "Sample": {"FM_Id": "ORD_1188306_01", "SampleId": "US1148014.01", "BlockId": "S110-24512A", "TRFNumber": "ORD_1188306_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2021_09_14", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "30", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-99575", "MRN": "46795442", "FullName": "\u90ed\u91d1\u6e76", "FirstName": "Chin_Chuan", "LastName": "Kuo", "SubmittedDiagnosis": "Glioblastoma, Cerebrum", "Gender": "Male", "DOB": "1961_03_20", "OrderingMD": "\u90ed\u91d1\u6e76", "OrderingMDId": "53741", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Brain", "CollDate": "2021_08_24", "ReceivedDate": "2021-09-24 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Diffuse Glioma"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "EGFR"}, {"Gene": "IDH1"}]}, "Summaries": {"alterationCount": "41", "clinicalTrialCount": "38", "resistiveCount": "0", "sensitizingCount": "2"}, "VariantProperties": {"VariantProperty": [{"geneName": "AXIN1", "isVUS": "true", "variantName": "A526V"}, {"geneName": "BAP1", "isVUS": "true", "variantName": "R700W"}, {"geneName": "BARD1", "isVUS": "true", "variantName": "P395S"}, {"geneName": "BCORL1", "isVUS": "true", "variantName": "D1015N"}, {"geneName": "CALR", "isVUS": "true", "variantName": "K111E"}, {"geneName": "DOT1L", "isVUS": "true", "variantName": "D588E"}, {"geneName": "EGFR", "isVUS": "true", "variantName": "R255*"}, {"geneName": "FGFR1", "isVUS": "true", "variantName": "D501E"}, {"geneName": "JAK3", "isVUS": "true", "variantName": "R222H"}, {"geneName": "KIT", "isVUS": "true", "variantName": "R956Q"}, {"geneName": "MAP2K2 (MEK2)", "isVUS": "true", "variantName": "E167K"}, {"geneName": "MSH2", "isVUS": "true", "variantName": "G164W"}, {"geneName": "MSH6", "isVUS": "true", "variantName": "K854del"}, {"geneName": "MTOR", "isVUS": "true", "variantName": "G1431R"}, {"geneName": "NF1", "isVUS": "true", "variantName": "R1412G"}, {"geneName": "PAX5", "isVUS": "true", "variantName": "R38C"}, {"geneName": "POLE", "isVUS": "true", "variantName": "R1839H"}, {"geneName": "PRKCI", "isVUS": "true", "variantName": "R130H"}, {"geneName": "RBM10", "isVUS": "true", "variantName": "R660H"}, {"geneName": "RPTOR", "isVUS": "true", "variantName": "P368L,V971I"}, {"geneName": "SYK", "isVUS": "true", "variantName": "splice site 1582_1G>T"}, {"geneName": "TBX3", "isVUS": "true", "variantName": "A562V"}, {"geneName": "TNFAIP3", "isVUS": "true", "variantName": "P462L"}, {"geneName": "ZNF703", "isVUS": "true", "variantName": "G340S"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "V14I", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "V14I"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). KRAS mutations K5N, V14I, P34L/R, T58I, G60R, Y71H, K147E, and F156L have been characterized as activating and identified as germline mutations associated with Noonan, Costello and cardio_faciocutaneous syndromes (Gremer et al., 2011; 20949621, Lee et al., 2003; 14534542, Schubbert et al., 2006; 16474405, Schubbert et al., 2007; 17875937, Gripp et al., 2008; 18247425, Kratz et al., 2007; 17211612, Cirstea et al., 2013; 23059812, Stark et al., 2012; 21797849). In the TCGA dataset, KRAS mutations or amplification was detected in 1.8% of glioblastomas (GBM)(cBio_Brennan et al., 2013; 24120142) and 2.8% of lower grade gliomas (Cancer Genome Atlas Research Network., 2015; 26061751). In other studies KRAS mutations were observed in 2 out of 125 pilocytic astrocytomas, 1 out 25 grade 1 and 2 astrocytomas (Cin et al., 2011; 21424530, Janzarik et al., 2007; 17712732), and 2 out of 94 patients with GBM (Knobbe et al., 2004; 15517309). While the importance of RAS signaling in astrocytomas has been established, there is very little information regarding clinical implications of KRAS alterations in human astrocytoma (Mellinghoff et al., 2011; 22015553, Cin et al., 2011; 21424530). In mouse models of cancer, activating KRAS mutation in combination with AKT mutation was sufficient to induce GBM in astrocytes and neural progenitors (Holland et al., 2000; 10802656). Furthermore, mutant KRAS_driven signaling was required for the maintenance of mouse GBM tumors (Holmen and Williams, 2005; 16166301), suggesting that targeting KRAS signaling may be an appropriate therapeutic strategy in KRAS_driven GBMs. Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors (Lu et al., 2019; 31068384, Mainardi et al., 2018; 29808006, Koczywas et al., 2021; AACR Abstract LB001, Brana et al., 2021; ASCO Abstract 3005, Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). A Phase 1 study of RMC_4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations (Koczywas et al., 2021; AACR Abstract LB001). Interim results from a Phase 1/2 study of RMC_4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS_mutated colorectal cancer (Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). While clinical responses have been reported for patients with KRAS_mutated ovarian (Monk et al., 2020; 32822286, Farley et al., 2013; 23261356, Pejovic et al., 2015; Am J Clin Exp Obstet Gynecol 2:140_143, Slosberg et al., 2018; 29765547, Han et al., 2018; 29946554), cervical small cell neuroendocrine (Lyons et al., 2014; 26075998), or uterine cancer (Slosberg et al., 2018; 29765547) treated with MEK inhibitor monotherapy, multiple clinical trials have not demonstrated increased response rates for patients with KRAS_altered tumors including KRAS_mutated CRC (Tsimberidou et al., 2013; ASCO Abstract e22086, Infante et al., 2012; 22805291, Zimmer et al., 2014; 24947927, Bennouna et al., 2011; 20127139, Weekes et al., 2013; 23434733), pancreatic cancer (Van Laethem et al., 2017; 27975152, Infante et al., 2014; 24915778, Van Cutsem et al., 2018; 29756206), and NSCLC (Blumenschein et al., 2015; 25722381, Leijen et al., 2012; 22767668, Zimmer et al., 2014; 24947927). A Phase 2 study of trametinib and uprosertib for patients with recurrent cervical cancer reported no responses for patients with KRAS_mutated (2/2 SDs) or KRAS_amplified (1/1 SD) cancer (Lui et al., 2019; 31118140). Clinical responses have been reported for combination treatment strategies including MEK inhibitors with PI3K or AKT inhibitors for patients with KRAS_mutated ovarian cancer (Spreafico et al., 2014; ASCO Abstract 5506, Juric et al., 2014; ASCO Abstract 9051, Banerji et al., 2014; ASCO Abstract e13559) and KRAS_mutated endometrioid adenocarcinoma (Shapiro et al., 2019; 31020608).", "Include": "true", "ClinicalTrialNote": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03284502", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03905148", "Include": "true"}, {"nctId": "NCT04111458", "Include": "true"}, {"nctId": "NCT04800822", "Include": "true"}, {"nctId": "NCT02070549", "Include": "true"}, {"nctId": "NCT02407509", "Include": "true"}, {"nctId": "NCT03162627", "Include": "true"}, {"nctId": "NCT03065387", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "NF1", "Include": "true", "Alterations": {"Alteration": {"Name": "S340fs*12", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "S340fs*12"}}, "Interpretation": "NF1 encodes neurofibromin, a GTPase_activating protein (GAP) that is a key negative regulator of the RAS signaling pathway (Hattori et al., 1991; 1904223). Neurofibromin acts as a tumor suppressor by repressing RAS signaling (Morcos et al., 1996; 8628317). Alterations such as seen here may disrupt NF1 function or expression (Ballester et al., 1990; 2121371, Xu et al., 1990; 2116237, Martin et al., 1990; 2121370, Thomas et al., 2012; 22807134, Skuse and Cappione, 1997; 9300663, Morcos et al., 1996; 8628317, Messiaen et al., 1999; 11258625, Ars et al., 2000; 10607834, Messiaen and Wimmer, 2005; 15863657, Poullet et al., 1994; 8264648). NF1 mutation has been observed in 5_6% of lower grade gliomas and 9_14% of glioblastoma multiforme (GBM) cases; homozygous deletion of NF1 was observed in 1% of lower grade gliomas and 2_3% of GBMs (Cancer Genome Atlas Research Network., 2015; 26061751, cBio_Johnson et al., 2014; 24336570, cBio_Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2008; 18772890). Among GBM subtypes, NF1 mutation and loss were reported most frequently in the mesenchymal subtype, 37% (14/28) and 38% (21/55) of cases, respectively (Verhaak et al., 2010; 20129251). NF1 loss was significantly associated with decreased overall and disease_specific survival in patients with lower grade gliomas (II_III), but not in those with GBM (Vizcaino et al., 2015; 26190195). On the basis of clinical evidence in neurofibromatosis Type 1_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma or glioblastoma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors such as cobimetinib, trametinib, binimetinib, and selumetinib. Loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors, including the approved agents everolimus and temsirolimus, based on limited clinical data (Lim et al., 2016; 26859683, Weiss et al., 2015; 25314964, Janku et al., 2014; 24931142) and strong preclinical data in models of malignant peripheral nerve sheath tumor (MPNST)(Johannessen et al., 2008; 18164202, Johannessen et al., 2005; 15937108). A preclinical study suggests that combined mTOR and MEK inhibition is effective in a model of NF1_deficient MPNST (Malone et al., 2014; 24913553). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). One or more of the NF1 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with neurofibromatosis type 1 (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in NF1 cause the autosomal dominant disorder neurofibromatosis type 1, which is characterized in part by increased risk of developing various tumors, including sarcoma, glioma, breast carcinoma, and neuroendocrine and hematological neoplasms (Jett and Friedman, 2010; 20027112, Patil and Chamberlain, 2012; 22240541, Evans et al., 2012; 23036231). Estimates for the prevalence of the disorder in the general population range from 1:2,500 to 1:3,000 (Upadhyaya et al., 1995; 8544190, Williams et al., 2009; 19117870), and in the appropriate clinical context, germline testing of NF1 is recommended.", "Include": "true", "ClinicalTrialNote": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Selumetinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PNs). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in neurofibromatosis type 1 (NF1)_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of selumetinib for the treatment of glioblastoma are limited (PubMed, Apr 2021). Selumetinib has demonstrated clinical activity in low_grade glioma. A Phase 2 study of selumetinib for patients with low_grade glioma (LGG) reported 8/25 PRs for patients with BRAF alterations and 10/25 PRs for those with NF1_associated LGG (Fangusaro et al., 2019; 31151904); a Phase 1 study of selumetinib reported 5/25 PRs for patients with LGG (Banerjee et al., 2017; 28339824). A Phase 2 study of selumetinib for patients with tumors with activating alterations in the MAPK pathway evaluated 8 patients with high_grade glioma (HGG); 2 SDs and no objective responses were observed in this subset (Allen et al., 2021; ASCO Abstract 10008). Selumetinib has demonstrated efficacy in NF1_associated neurofibroma in Phase 2 studies (Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612) and a Phase 1 study (Dombi et al., 2016; 28029918). Phase 2 studies reported clinical responses in low_grade glioma (Fangusaro et al., 2019; 31151904, Banerjee et al., 2017; 28339824), melanoma (Gupta et al., 2014; 24567366, Robert et al., 2013; 23735514, Kirkwood et al., 2012; 22048237, Banerji et al., 2010; 20179232, Boers_Sonderen et al., 2012; 22293660), and in lung (Lopez_Chavez et al., 2015; 25667274, Hainsworth et al., 2010; 20802351, Middleton et al., 2020; 32669708) and endometrial cancer (Coleman et al., 2015; 25887099). A Phase 2 study of selumetinib for patients with activating alterations in the MAPK pathway reported a DCR of 15% (3/20), with no objective responses observed (Allen et al., 2021; ASCO Abstract 10008). Phase 1 studies of selumetinib to treat patients with solid tumors reported 1/15 PR for a patient with colorectal cancer (CRC) and 5/15 SDs for patients with tonsil squamous cell carcinoma (SCC), non_small cell lung cancer (NSCLC), and CRC (Deming et al., 2016; 26666244); 2/39 PRs (for patients with CRC) and 18/39 SDs were achieved when selumetinib was administered in combination with cyclosporin A (Krishnamurthy et al., 2018; 30042150). Multiple Phase 1 studies combining selumetinib with erlotinib or temsirolimus (Infante et al., 2017; 28424891), docetaxel or dacarbazine (LoRusso et al., 2017; 28264648), AKT inhibitors (Tolcher et al., 2015; 25516890), or cixutumumab (an anti_IGF_1R antibody)(Wilky et al., 2015; 25268371) reported clinical responses for patients with advanced solid tumors including NSCLC, thyroid carcinoma, tongue SCC, and ovarian cancer. </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Trametinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in neurofibromatosis type 1 (NF1)_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> Case studies of trametinib in NF1_associated low_grade glioma have reported 7 PRs, including 2 patients with pilocytic astrocytoma, 2 patients with diffuse astrocytoma, 3 patients with low_grade glioma experiencing PRs of over 6 months (Manoharan et al., 2020; 32780261, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Kondyli et al., 2018; 30097824). A study of four pediatric patients with BRAF mutation_positive non_operable astrocytoma reported a reduction in tumor volume in response to trametinib for the 3 optic gliomas with BRAF duplication (Miller et al., 2016; ISPNO Abstract LG_01, Miller et al., 2016; 28009226). A patient with pilocytic astrocytoma harboring an NFIA_RAF1 fusion that had progressed on multiple lines of prior treatment exhibited ongoing SD following treatment with trametinib (Yde et al., 2016; 27810072). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03834740", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03905148", "Include": "true"}, {"nctId": "NCT03158389", "Include": "true"}, {"nctId": "NCT04800822", "Include": "true"}, {"nctId": "NCT02070549", "Include": "true"}, {"nctId": "NCT03065062", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PDGFRA", "Include": "true", "Alterations": {"Alteration": {"Name": "S847L", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "S847L"}}, "Interpretation": "PDGFRA encodes platelet_derived growth factor receptor alpha (PDGFR_alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK (Andrae et al., 2008; 18483217). PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies (Fletcher, 2004; 15175998). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. PDGFRA mutation has been identified in 5.6% of Grade 3 and 5.4% of Grade 4 astrocytomas, 2.4% of Grade 3 oligodendrogliomas, and 12% (3/25) of gliosarcomas analyzed in COSMIC (Jun 2021)(Tate et al., 2019; 30371878). PDGFRA mutations have been reported in 0_5% of lower grade glioma and glioblastoma samples (cBio_Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2008; 18772890, cBio_Hoadley et al., 2018; 29625048, cBio_Ellrott et al., 2018; 29596782, cBio_Taylor et al., 2018; 29622463, cBio_Gao et al., 2018; 29617662, cBio_Liu et al., 2018; 29625055, cBio_Sanchez_Vega et al., 2018; 29625050), Ceccarelli et al., 2016; 26824661, Cancer Genome Atlas Research Network., 2015; 26061751, cBio_Johnson et al., 2014; 24336570, cBio_Thomas et al., 2017; 28472509, cBio_Jones et al., 2013; 23817572). A retrospective analysis of TCGA glioma samples reported elevated expression of ERBB3 correlated with PDGFRA expression and co_expression of these genes was an indicator of poor prognosis in a GBM patient cohort (Song et al., 2018; 29888103). Amplification of PDGFRA has been associated with tumor grade and poor progression_free and overall survival in patients with glioblastoma (Alentorn et al., 2012; 23074200, Sottoriva et al., 2013; 23412337, Phillips et al., 2013; 23438035). In addition, PDGFRA amplification has been reported to occur in conjunction with IDH1 mutation in glioblastoma, and both alterations in the same tumor have been associated with poor patient prognosis (Phillips et al., 2013; 23438035). On the basis of extensive clinical evidence in solid tumors and hematologic cancers, PDGFRA activating alterations are associated with sensitivity to imatinib (Arefi et al., 2012; 22806436, Baccarani et al., 2007; 17666373, Cassier et al., 2012; 22718859, Chalmers et al., 2015; 25658984, Cools et al., 2003; 12660384, Curtis et al., 2007; 17555450, Debiec_Rychter et al., 2016; 15010069, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Florian et al., 2006; 16406018, Frenard et al., 2016; 27051816, Griffin et al., 2003; 12808148, Heinrich et al., 2003; 14645423, Helbig et al., 2009; 19120352, Helbig et al., 2014; 24009127, Hus et al., 2011; 21093052, Ikezoe et al., 2010; 20303172, Intermesoli et al., 2009; 19735261, Jain et al., 2009; 19013640, Jovanovic et al., 2007; 17299092, Kang et al., 2012; 22150077, Klion et al., 2004; 14504092, Kobayashi et al., 2009; 19192229, Koc\u00e1kov\u00e1 et al., 2014; 24635438, Metzgeroth et al., 2008; 18950453, Murayama et al., 2012; 22645636, Ogbogu et al., 2009; 19910029, Ohnishi et al., 2006; 16856885, Pardanani et al., 2003; 12842979, Pardanani et al., 2004; 15284118, Qu et al., 2016; 27120808, Score et al., 2006; 16498388, Shah et al., 2011; 24669761, Sugimoto et al., 2015; 26319757, Volz et al., 2011; 20609486, von Bubnoff et al., 2005; 15618966, Walz et al., 2006; 16845659, Yoo et al., 2016; 26130666). Sorafenib has shown clinical and preclinical activity against the FIP1L1_PDGFRA fusion in chronic eosinophilic leukemia (CEL) and mutations associated with clinical resistance to imatinib and sunitinib in both CEL and gastrointestinal stromal tumor (GIST)(Fumagalli et al., 2012; ESMO Abstract 1491P, Al_Riyami et al., 2013; 23157309, Lierman et al., 2006; 16645167, Lierman et al., 2009; 19212337, Metzgeroth et al., 2012; 21818111, Roubaud et al., 2012; 22294526, Von Bubnoff et al., 2011; 20972453). Complete responses to nilotinib have been reported in patients with CEL or hypereosinophilic syndrome with FIP1L1_PDGFRA or activating mutations (Hochhaus et al., 2013; 24057647, Ikezoe et al., 2010; 20303172, Tabouret et al., 2011; 20832858); preclinical evidence has reported efficacy of nilotinib in the context of PDGFRA mutations associated with GIST (Dewaele et al., 2008; 18794084, Weisberg et al., 2006; 17087936). Patients with GIST harboring PDGFRA activating mutations have been reported to derive clinical benefit from treatment with sunitinib (Heinrich et al., 2006; ASCO Abstract 9502, Brohl et al., 2015; 26396737) or regorafenib (Grellety et al., 2015; 28031906, Kollar et al., 2014; 25905001). Preclinical studies have reported sensitivity of activating PDGFRA mutations and FIP1L1_PDGFRA fusion to dasatinib (Dewaele et al., 2008; 18794084, Lierman et al., 2009; 19212337). PDGFRA D842 mutations were reported to be sensitive to avapritinib in clinical (Heinrich et al., 2017; ASCO Abstract 11011, Evans et al., 2017; 29093181) and preclinical (Evans et al., 2017; 29093181) studies of GIST, and demonstrated sensitivity to ripretinib for 1 patient (Jaku et al., 2017; ASCO Abstract 2515). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true", "ClinicalTrialNote": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04704154", "Include": "true"}, {"nctId": "NCT03025893", "Include": "true"}, {"nctId": "NCT03970447", "Include": "true"}, {"nctId": "NCT04051606", "Include": "true"}, {"nctId": "NCT04200404", "Include": "true"}, {"nctId": "NCT02379416", "Include": "true"}, {"nctId": "NCT03475251", "Include": "true"}, {"nctId": "NCT01738139", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PTEN", "Include": "true", "Alterations": {"Alteration": {"Name": "R233*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R233*"}}, "Interpretation": "PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodr\u00edguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andr\u00e9s_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454). Studies in the literature have indicated that PTEN alterations (mutation or homozygous deletion) occur most frequently in glioblastoma (GBM), less frequently in anaplastic astrocytoma, and rarely in lower grade glioma subtypes including low grade astrocytoma, oligodendroglioma, oligoastrocytoma, and ependymoma (Zhou et al., 1999; 10096247, Rasheed et al., 1997; 9331072, Davies et al., 1999; 10188904, Smith et al., 2001; 11504770, Lin et al., 1998; 9796977, Schmidt et al., 1999; 10560660, Kato et al., 2000; 11051241, Furnari et al., 2007; 17974913). One study detected PTEN mutation in 42% (97/232) and loss in 10% (24/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). In the TCGA dataset, PTEN mutation was observed in 23% of GBM cases and PTEN deletion was reported in 7% of cases (cBio_Brennan et al., 2013; 24120142), while in the Lower Grade Glioma TCGA dataset, PTEN mutation was observed in 4% of cases and homozygous deletion observed in 1.2% of cases (Cancer Genome Atlas Research Network., 2015; 26061751). Decreased PTEN expression is associated with the higher grade GBM tumors (Sano et al., 1999; 10213484). Loss of PTEN correlated with significantly worse prognosis in all grades of gliomas (Lin et al., 1998; 9796977, Srividya et al., 2011; 21134002). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Clinical studies in glioblastoma have not observed an association between PTEN deficiency and response to everolimus or temsirolimus (Galanis et al., 2005; 15998902, Kreisl et al., 2009; 19018475, Mason et al., 2011; 22160854). Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). On the basis of a Phase 1b study, PTEN loss of expression may be associated with resistance to combination therapy with CDK4/6 inhibitors such as ribociclib and aromatase inhibitors such as letrozole (Costa et al., 2019; 31594766). Limited clinical evidence in glioblastoma (Zhao et al., 2019; 30742119, Peiwen et al., 2019; AACR Abstract A060), leiomyosarcoma (George et al., 2017; 28228279), and melanoma (Peng et al., 2016; 26645196) suggests that PTEN alterations may predict a lack of response to anti_PD_1 therapy. In an analysis of 39 patients with metastatic melanoma treated with pembrolizumab or nivolumab, patients with PTEN_expressing tumors achieved significantly greater reduction of tumor size than those with reduction or loss of PTEN expression (Peng et al., 2016; 26645196). In a retrospective analysis of 66 patients with glioblastoma, tumors from nivolumab or pembrolizumab non_responders were significantly enriched for PTEN mutations (Zhao et al., 2019; 30742119, Peiwen et al., 2019; AACR Abstract A060). In a patient with uterine leiomyosarcoma treated with pembrolizumab monotherapy, a treatment_resistant tumor arose that harbored PTEN loss (George et al., 2017; 28228279). One or more of the PTEN variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hamartoma tumor syndrome (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.", "Include": "true", "ClinicalTrialNote": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04740190", "Include": "true"}, {"nctId": "NCT04001569", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04715620", "Include": "true"}, {"nctId": "NCT04635631", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04632992", "Include": "true"}, {"nctId": "NCT04497116", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "RNF43", "Include": "true", "Alterations": {"Alteration": {"Name": "G659fs*41", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "G659fs*41"}}, "Interpretation": "RNF43 encodes a ubiquitin ligase (Sugiura et al., 2008; 18313049) that was discovered because it is overexpressed in colon cancer (Yagyu et al., 2004; 15492824). RNF43 and the homologous E3 ubiquitin ligase ZNRF3 are tumor suppressors that function as negative regulators of WNT signaling (Hao et al., 2012; 22575959, Koo et al., 2012; 22895187, Jiang et al., 2013; 23847203, Koo et al., 2015; 26023187, Tsukiyama et al., 2015; 25825523). An additional tumor_suppressor_like role for RNF43 in colon cancer is hypothesized to occur via its interaction with the ubiquitin_protein ligase NEDL1, which is predicted to enhance the pro_apoptotic effects of p53 (Shinada et al., 2011; 21108931). Mutations in RNF43 have been reported in 18_27% of endometrial cancers (Kinde et al., 2013; 23303603, Giannakis et al., 2014; 25344691), 3_5% of pancreatic cancers (Madan and Virshup, 2015; 25901018), 21% of ovarian mucinous carcinomas (Ryland et al., 2013; 23096461), 9% of liver fluke_associated cholangiocarcinomas (Ong et al., 2012; 22561520), and up to 18% of colorectal cancers (Giannakis et al., 2014; 25344691, Cancer Genome Atlas Network., 2012; 22810696). RNF43 mutations are associated with mismatch repair deficiency and microsatellite instability (MSI) in colorectal (Giannakis et al., 2014; 25344691), endometrial (Giannakis et al., 2014; 25344691), and gastric cancers (Wang et al., 2014; 24816253, Cancer Genome Atlas Research Network., 2014; 25079317); one study reported RNF43 alterations in more than 50% of MSI gastric carcinomas (Wang et al., 2014; 24816253). Preclinical studies have reported that RNF43 is a negative regulator of WNT signaling, and RNF43 loss or inactivation leads to WNT activation and confers sensitivity to WNT pathway inhibitors, particularly Porcupine inhibitors, in multiple tumor types (Hao et al., 2012; 22575959, Koo et al., 2012; 22895187, Jiang et al., 2013; 23847203, Koo et al., 2015; 26023187, Tsukiyama et al., 2015; 25825523). Therefore, patients whose tumors harbor inactivating alterations in RNF43 may benefit from WNT pathway inhibitors, which are under investigation in clinical trials.", "Include": "true", "ClinicalTrialNote": "Based on preclinical evidence, tumors with loss or inactivation of RNF43 may be sensitive to inhibitors of the WNT signaling pathway.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT02521844", "Include": "true"}, {"nctId": "NCT01351103", "Include": "true"}, {"nctId": "NCT03447470", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "TSC2", "Include": "true", "Alterations": {"Alteration": {"Name": "R1438Q", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R1438Q"}}, "Interpretation": "The tumor suppressor protein Tuberin (TSC2) binds with Hamartin (TSC1) to inhibit mTOR signaling and cell growth (Inoki et al., 2003; 12869586, Tee et al., 2003; 12906785). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. Hemizygous loss of TSC2 has been reported in one of 15 GBM samples in one study (Parry et al., 2000; 11129334) and homozygous deletion in 0.2% of cases analyzed in the TCGA datasets (cBio_Brennan et al., 2013; 24120142). TSC2 mutation has been observed in 0.4_3.0% of grade I_II glioma, 2.8% of grade III glioma, and <0.5% of glioblastomas (cBioPortal, COSMIC, Jan 2021)(cBio_Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2015; 26061751). Loss of Tuberin expression has been reported in high_grade astrocytomas (Lau et al., 2003; 12469204). Inactivation of TSC2 and Tuberin has been associated with numerous cancers, including astrocytomas and glioblastomas (Rosner et al., 2009; 19286253, Riemenschneider et al., 2006; 16740698). Loss or inactivation of TSC2 can activate mTOR signaling (Tee et al., 2003; 12906785, Mallela et al., 2021; 33575875). MTOR inhibitors such as everolimus, temsirolimus, and sirolimus have shown activity against tumors associated with the genetic disease tuberous sclerosis complex (TSC), including subependymal giant_cell astrocytomas and renal angiomyolipomas (Kwiatkowski et al., 2015; 25782670, Choi et al., 2020; EAU Abstract 103, Wang et al., 2020; 31597506, Guo et al., 2021; 33575217, Espinosa et al., 2018; 29764404, Chuang et al., 2017; 28547571). In the context of TSC2_altered malignancies unrelated to TSC, MTOR inhibitor activity has been limited (Adib et al., 2021; 33727259, Nassar et al., 2020; 31653662, Voss et al., 2019; 3032730), with the exception of perivascular epithelioid cell tumors (PEComas)(Wagner et al., 2010; 20048174, Dickson et al., 2013; 22927055) and anecdotal reports across various solid tumors including anaplastic thyroid cancer (Wagle et al., 2014; 25295501), renal cell carcinoma (RCC)(Tannir et al., 2015; 26626617, Maroto et al., 2018; 29632054), glioblastoma (Zureick et al., 2019; 31154346), and CNS embryonal tumor (Wu et al., 2020; 33344249), as well as a case of Hodgkin lymphoma (Perini et al., 2016; 27176796). In the prospective NCI_MATCH study, only 6.7% (1/15) of patients with TSC2_mutated solid tumors responded to everolimus, with the single response reported for a patient with uterine leiomyosarcoma (Adib et al., 2021; 33727259). Retrospective analyses of the RECORD_3, GRANITE_1, and EVOLVE_1 studies of everolimus to treat patients with RCC, gastric cancer, or hepatocellular carcinoma, respectively, showed no significant association between alterations in MTOR, TSC1, or TSC2 and median PFS (Voss et al., 2019; 30327302). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. Inactivating germline mutations in TSC2 are associated with the autosomal dominant disorder tuberous sclerosis complex, which results in the development of hamartomas in multiple organ systems and an increased risk of developing renal cell carcinoma (RCC) (Gomez, 1991; 2039135, Kandt et al., 1992; 1303246, European Chromosome 16 Tuberous Sclerosis Consortium, 1993; 8269512). TSC2 mutations account for approximately 75 to 80% of reported sporadic cases (Curatolo et al., 2008; 18722871). Prevalence for this disorder in the general population is estimated to be 1/6,000 from birth and 1/12,000 to 1/14,000 in children under 10 years of age (Curatolo et al., 2008; 18722871). In the appropriate clinical context, germline testing of TSC2 is recommended.", "Include": "true", "ClinicalTrialNote": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03834740", "Include": "true"}, {"nctId": "NCT03158389", "Include": "true"}, {"nctId": "NCT03065062", "Include": "true"}, {"nctId": "NCT02159989", "Include": "true"}, {"nctId": "NCT03217669", "Include": "true"}, {"nctId": "NCT01552434", "Include": "true"}, {"nctId": "NCT01582191", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "ATR", "Include": "true", "Alterations": {"Alteration": {"Name": "Y2025fs*2", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Y2025fs*2"}}, "Interpretation": "ATR encodes the protein ataxia telangiectasia and RAD3 related, which phosphorylates the tumor suppressor BRCA1, and several cell cycle checkpoint proteins including CHK1; it plays a key role in maintaining genome integrity via regulation of DNA repair and replication (Ha et al., 2011; 21566061, Liang et al., 2009; 19034564). Alterations such as seen here may disrupt ATR function or expression (Mordes et al., 2008; 18519640). ATR mutations have been reported in 1% of glioblastoma multiforme (GBM) samples (cBio_Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2008; 18772890). In the COSMIC database, ATR mutations were not detected in any of 70 low_grade gliomas, but were identified in 2% of glioblastomas (Apr 2021)(Tate et al., 2019; 30371878). Expression of ATR has been reported to be reduced in gliomas compared to normal brain tissue (Wang et al., 2010; 19969004). It has also been reported that in glioma cells the level of phosphorylated ATR decreases in response to hypoxia (Levin et al., 2012; 22276931). The prognostic significance of ATR alterations in glioma has not been extensively investigated (PubMed, Mar 2021). A Phase 2 study reported talazoparib led to a SD lasting over 6 months for a patient with ATR_mutated breast cancer (Gruber et al., 2019; ASCO Abstract 3006). Based on preclinical evidence, ATR_deficient tumors may be sensitive to PARP inhibitors (Peasland et al., 2011; 21730979, McCabe et al., 2006; 16912188). ATR inactivation has been associated with increased sensitivity to 5_fluorouracil and cisplatin, but not to oxaliplatin, in cancer cell lines (Jardim et al., 2009; 19570909, Lewis et al., 2009; 1937255, Sangster_Guity et al., 2011; 21258400); however, this has not been demonstrated clinically.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": {"Name": "p16INK4a R58* and p14ARF P72L", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "p16INK4a R58* and p14ARF P72L"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here have been observed in the context of cancer but have not been characterized and their effect on p14ARF function is unclear. Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas (cBio_Ceccarelli et al., 2016; 26824661) and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)(cBio_Brennan et al., 2013; 24120142) than in those with lower grade gliomas (13%) (cBioPortal, Sep 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM) (Verhaak et al., 2010; 20129251, Sottoriva et al., 2013; 23412337, Weber et al., 2007; 16909113). A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF_encoding locus alone (Nakamura et al., 2001; 11303791). One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples (Chakravarti et al., 2001; 11489817). Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression (Feng et al., 2012; 21713760, Sottoriva et al., 2013; 23412337). In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas (Raabe et al., 2011; 21636552, Liu et al., 2011; 21843312). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889), multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. On the basis of a Phase 1b study, PTEN loss of expression may be associated with resistance to combination therapy with CDK4/6 inhibitors such as ribociclib and aromatase inhibitors such as letrozole (Costa et al., 2019; 31594766). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "ERCC4", "Include": "true", "Alterations": {"Alteration": {"Name": "A428V", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "A428V"}}, "Interpretation": "ERCC4 (also known as XPF) encodes a DNA endonuclease that forms an obligate partner for ERCC1; XPF_ERCC1 is involved in several DNA repair pathways, including nucleotide excision repair (NER), interstrand cross_link repair, single\u2010stranded annealing branch of homologous recombination, and telomere maintenance (Sch\u00e4rer., 2017; 28659377, McNeil and Melton., 2012; 22941649). Cells lacking ERCC4 exhibit heightened sensitivity to platinum agents (Ceccaldi et al., 2015; 25634215, Mohni et al., 2015; 25965342). Mutations in ERCC4 have been associated with xeroderma pigmentosum, Cockayne syndrome, Fanconi anemia, XFE progeria, and cerebro_oculo_facio_skeletal syndrome (Manandhar et al., 2015; 26074087). In the MSK_IMPACT pan_cancer dataset, ERCC4 mutation has been reported in 1.2% of more than 10,000 samples across 62 solid tumor types analyzed (Zehir et al., 2017; 28481359). In lung adenocarcinoma, higher expression of XPF was observed in never smokers versus ever smokers (Planchard et al., 2009; 19297315). High expression of the partner protein, ERCC1, has been associated with lack of response to platinum_based chemotherapy in several tumor types, including non_small cell lung cancer (Simon et al., 2005; 15764785, Olaussen et al., 2006;16957145), head and neck squamous cell carcinoma (Jun et al., 2008; 18594541), bladder cancer (Bellmunt et al., 2007; 17229776), and ovarian cancer (Ferry et al., 2000; 11008124, McNeil and Melton., 2012; 22941649). There are no therapies to address ERCC4 alterations in cancer. On the basis of limited preclinical and clinical data, loss of ERCC4 expression may predict response to platinum agents (Ceccaldi et al., 2015; 25634215, Mohni et al., 2015; 25965342) or combination PARP and TOP1 inhibitors (Zhang et al., 2011; 21227924). A patient with advanced_stage high_grade serous epithelial ovarian cancer and an ERCC4 A583T mutation with heterozygous loss of the wild_type allele exhibited an ongoing disease_free response (25 months post diagnosis) to first_line platinum chemotherapy (Ceccaldi et al., 2015; 25634215).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. Low_level MSI has been reported in 5_9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large_scale study did not find high_level microsatellite instability (MSI_H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small_scale study reported MSI_H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). On the basis of prospective clinical evidence in multiple solid tumor types, MSI and associated increased mutational burden (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to anti_PD_1 and anti_PD_L1 immune checkpoint inhibitors (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92)(Gatalica et al., 2014; 25392179, Lal et al., 2015; 25949894), including the approved therapies nivolumab (alone or in combination with ipilimumab) (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Lipson et al., 2013; 23169436), pembrolizumab (Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070), atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear. While approximately 80% of MSI_H tumors arise due to somatic inactivation of an MMR pathway protein, about 20% arise due to germline mutations in one of the MMR genes (Kocarnik et al., 2015; 26337942), which are associated with a condition known as Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) (Lynch et al., 2009; 19659756). Lynch syndrome leads to an increased risk of colorectal, endometrial, gastric, and other cancers (Lynch et al., 2009; 19659756, Pande et al., 2012; 22714864, Kastrinos and Syngal, 2007; 17920897) and has an estimated prevalence in the general population ranging from 1:600 to 1:2000 (Silva et al., 2009; 19466295, Sehgal et al., 2014; 24978665, de la Chapelle et al., 2005; 16136383). Therefore, in the appropriate clinical context, germline testing of MLH1, MSH2, MSH6, and PMS2 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "PTPN11", "Include": "true", "Alterations": {"Alteration": [{"Name": "M504V", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "M504V"}}, "Interpretation": "PTPN11 encodes the protein tyrosine_protein phosphatase non_receptor type 11, also known as SHP_2. PTPN11 plays a critical role in both embryonic development and cancer (Grossmann et al., 2010; 20399956). PTPN11 is also known to be somatically mutated in a variety of cancers, where both oncogenic and tumor suppressor roles for PTPN11 have been described (Tartaglia et al., 2003; 12717436, Bard_Chapeau et al., 2011; 21575863, Sturla et al., 2011; 21934682). The N_terminal SRC homology 2 (SH2) domain (aa 6_102) negatively regulates SHP_2 activity by binding to the active site of the SHP_2 protein tyrosine phosphatase (PTP) domain (aa 247_521)(Hof et al., 1998; 9791886). Alterations that disrupt this interaction or affect the specificity and structure of the SH2 and PTP domains, such as seen here, have been characterized as activating (Chan et al., 2007; 17053061, Chan et al., 2005; 15644411, Tartaglia et al., 2003; 12717436, Tartaglia et al., 2006; 16358218, Wang et al., 2009; 19008228, Niihori et al., 2005; 15834506, Bentires_Alj et al., 2004; 15604238, O Reilly et al., 2000; 10594032, Eminaga et al., 2008; 18378677, Martinelli et al., 2012; 22711529, Eminaga and Bennett., 2008; 18378677, Edwards et al., 2014; 24891296, Yu et al., 2014; 24935154, Martinelli et al., 2008; 18372317, LaRochelle et al., 2016; 27030275, LaRochelle et al., 2018; 30375388) and are predicted to be oncogenic (Mohi et al., 2005; 15710330, Bentires_Alj et al., 2004; 15604238, Tartaglia et al., 2006; 16358218, Schubbert et al., 2005; 15761018, Chan et al., 2005; 15644411, Tartaglia et al., 2003; 12717436, Wang et al., 2009; 19008228, Niihori et al., 2005; 15834506, Chan et al., 2009; 19179468, Xu et al., 2010; 20651068). The PTPN11 R498W mutation was reported in a patient with Noonan syndrome and characterized as inactivating (Edwards et al., 2014; 24891296). In the Brain Lower Grade Glioma and Glioblastoma Multiforme TCGA datasets, PTPN11 mutations have been reported in fewer than 1% of cases (cBioPortal, Jan 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). PTPN11 mutations in glioma subtypes have also been reported in the scientific literature, and recurrent activating PTPN11 mutations have been detected in pilocytic astrocytomas (Sturla et al., 2011; 21934682, Jones et al., 2013; 23817572, Schuettpelz et al., 2009; 19621452). PTPN11 mutations in glioblastoma have been associated with young patient age (Ferguson et al., 2016; 27579614), but their prognostic significance in gliomas in general have not been extensively studied (PubMed, Aug 2021). While both oncogenic and tumor suppressor roles for PTPN11 has been described, its role in glioblastoma tumorigenesis is likely to be oncogenic (Jones et al., 2013; 23817572, Tartaglia et al., 2003; 12717436, Bard_Chapeau et al., 2011; 21575863, Sturla et al., 2011; 21934682). SHP_2 has been reported to activate the RAS_MEK_ERK, PI3K_AKT_mTOR, and SRC kinase pathways (Liu et al., 2011; 21393858, Feng et al., 2012; 21996738, Wang et al., 2009; 19008228, Zhou and Agazie, 2008; 18421299). Based on a case study of a patient with histiocytic sarcoma harboring an activating PTPN11 mutation who experienced a PR to trametinib (Voruz et al., 2018; 29097496), as well as preclinical data (Tasian et al., 2019; 29884903, Krenz et al., 2005; 16166557, Nakamura et al., 2009; 19706403), PTPN11 activation may predict sensitivity to MEK inhibitors in histiocytic neoplasms. These approaches would not be relevant in the context of inactivating alterations, as seen here. Germline mutations in PTPN11 have been found in the developmental disorder Noonan syndrome, which predisposes individuals to various cancers, including embryonal rhabdomyosarcoma, neuroblastoma, and juvenile myelomonocytic leukemia (Brasil et al., 2010; 20578946, Hasle, 2009; 20029231, Chen et al., 2006; 16518851, Tartaglia et al., 2006; 16358218, Pierpont et al., 2009; 19077116, Mathur et al., 2014; 24754368).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "R498W", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R498W"}}, "Interpretation": "PTPN11 encodes the protein tyrosine_protein phosphatase non_receptor type 11, also known as SHP_2. PTPN11 plays a critical role in both embryonic development and cancer (Grossmann et al., 2010; 20399956). PTPN11 is also known to be somatically mutated in a variety of cancers, where both oncogenic and tumor suppressor roles for PTPN11 have been described (Tartaglia et al., 2003; 12717436, Bard_Chapeau et al., 2011; 21575863, Sturla et al., 2011; 21934682). The N_terminal SRC homology 2 (SH2) domain (aa 6_102) negatively regulates SHP_2 activity by binding to the active site of the SHP_2 protein tyrosine phosphatase (PTP) domain (aa 247_521)(Hof et al., 1998; 9791886). Alterations that disrupt this interaction or affect the specificity and structure of the SH2 and PTP domains, such as seen here, have been characterized as activating (Chan et al., 2007; 17053061, Chan et al., 2005; 15644411, Tartaglia et al., 2003; 12717436, Tartaglia et al., 2006; 16358218, Wang et al., 2009; 19008228, Niihori et al., 2005; 15834506, Bentires_Alj et al., 2004; 15604238, O Reilly et al., 2000; 10594032, Eminaga et al., 2008; 18378677, Martinelli et al., 2012; 22711529, Eminaga and Bennett., 2008; 18378677, Edwards et al., 2014; 24891296, Yu et al., 2014; 24935154, Martinelli et al., 2008; 18372317, LaRochelle et al., 2016; 27030275, LaRochelle et al., 2018; 30375388) and are predicted to be oncogenic (Mohi et al., 2005; 15710330, Bentires_Alj et al., 2004; 15604238, Tartaglia et al., 2006; 16358218, Schubbert et al., 2005; 15761018, Chan et al., 2005; 15644411, Tartaglia et al., 2003; 12717436, Wang et al., 2009; 19008228, Niihori et al., 2005; 15834506, Chan et al., 2009; 19179468, Xu et al., 2010; 20651068). The PTPN11 R498W mutation was reported in a patient with Noonan syndrome and characterized as inactivating (Edwards et al., 2014; 24891296). In the Brain Lower Grade Glioma and Glioblastoma Multiforme TCGA datasets, PTPN11 mutations have been reported in fewer than 1% of cases (cBioPortal, Jan 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). PTPN11 mutations in glioma subtypes have also been reported in the scientific literature, and recurrent activating PTPN11 mutations have been detected in pilocytic astrocytomas (Sturla et al., 2011; 21934682, Jones et al., 2013; 23817572, Schuettpelz et al., 2009; 19621452). PTPN11 mutations in glioblastoma have been associated with young patient age (Ferguson et al., 2016; 27579614), but their prognostic significance in gliomas in general have not been extensively studied (PubMed, Aug 2021). While both oncogenic and tumor suppressor roles for PTPN11 has been described, its role in glioblastoma tumorigenesis is likely to be oncogenic (Jones et al., 2013; 23817572, Tartaglia et al., 2003; 12717436, Bard_Chapeau et al., 2011; 21575863, Sturla et al., 2011; 21934682). SHP_2 has been reported to activate the RAS_MEK_ERK, PI3K_AKT_mTOR, and SRC kinase pathways (Liu et al., 2011; 21393858, Feng et al., 2012; 21996738, Wang et al., 2009; 19008228, Zhou and Agazie, 2008; 18421299). Based on a case study of a patient with histiocytic sarcoma harboring an activating PTPN11 mutation who experienced a PR to trametinib (Voruz et al., 2018; 29097496), as well as preclinical data (Tasian et al., 2019; 29884903, Krenz et al., 2005; 16166557, Nakamura et al., 2009; 19706403), PTPN11 activation may predict sensitivity to MEK inhibitors in histiocytic neoplasms. These approaches would not be relevant in the context of inactivating alterations, as seen here. Germline mutations in PTPN11 have been found in the developmental disorder Noonan syndrome, which predisposes individuals to various cancers, including embryonal rhabdomyosarcoma, neuroblastoma, and juvenile myelomonocytic leukemia (Brasil et al., 2010; 20578946, Hasle, 2009; 20029231, Chen et al., 2006; 16518851, Tartaglia et al., 2006; 16358218, Pierpont et al., 2009; 19077116, Mathur et al., 2014; 24754368).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "SETD2", "Include": "true", "Alterations": {"Alteration": {"Name": "W1640fs*26", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "W1640fs*26"}}, "Interpretation": "SETD2 encodes a histone lysine_36 methyltransferase (Sun et al., 2005; 16118227) that preferentially interacts with the expanded N_terminal polyglutamine tracts present in mutant huntingtin, implicating it in the pathogenesis of Huntington disease (Faber et al., 1998; 9700202). SETD2 mRNA expression has been observed to be consistently reduced in breast tumors relative to adjacent non_tumor tissue, suggesting a potential tumor suppressor role (Al Sarakbi et al., 2009; 19698110). SETD2 alterations such as observed here have been shown to be inactivating (Parker et al., 2016; 27282254, Zhang et al., 2012; 22237106, McKinney et al., 2017; 28122867, Moffitt et al., 2017; 28424246, Zhu et al., 2014; 24509477, Lu et al., 2016; 27174990). Somatic inactivating alterations of SETD2 are documented to occur at low frequency in a number of solid tumors, most commonly in renal carcinoma (Varela et al., 2011; 21248752). SETD2 has been associated with favorable prognosis in gastric cancer (Chen et al., 2018; 29522714). SETD2 has also been associated with poor prognosis in RCC and MDS (Chen et al., 2020; 32202636, Liu et al.,; 2015; 26559293), while data in other tumor types is limited (PubMed, Jun 2021). There are no targeted therapies available to address genomic alterations in SETD2.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": [{"Name": "R110C", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R110C"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). In the TCGA dataset, TP53 alterations have been reported in 35% of glioblastomas (GBMs), with a high incidence in pediatric and secondary GBMs and a low incidence in primary GBMs (Cancer Genome Atlas Research Network., 2008; 18772890, Jha et al., 2011; 22089350). One study detected TP53 alterations in 31% (73/232) of IDH_wildtype GBM samples analyzed, with most of the events being mutations (Yan et al. 2020; DOI:10.1200/PO.19.00385). TP53 mutations have been reported in 18_40% of astrocytoma samples, and preferentially in anaplastic astrocytoma; one study reported TP53 loss of function and partially/fully functional mutations in 15% and 25% of anaplastic astrocytomas, respectively (Uno et al., 2005; 15914282, Uno et al., 2006; 16711514, Lass et al., 2012; 22844452, Faria et al., 2012; 23009112, Milinkovic et al., 2013; 24358143, Galatro et al., 2013; 23613880). Some studies suggest that the presence of a TP53 mutation is correlated with a favorable prognosis in patients with glioblastoma (GBM) (Schmidt et al., 2002; 11939587). One study reported that TP53 alterations were associated with poorer OS (12.9 months altered vs. 19.7 months wildtype, HR=1.58, p=0.0054) in IDH_wildtype GBM (Yan et al. 2020; DOI:10.1200/PO.19.00385). Mutation of TP53 is thought to be an early step in the tumorigenesis of astrocytomas, which can progress into anaplastic astrocytoma and then glioblastoma through gain of other genetic abnormalities such as loss of CDKN2A or RB1, followed by loss of PTEN (Nozaki et al., 1999; 11550308). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) in patients with TP53 mutations versus 12.1% (4/33) in patients who were TP53 wild_type (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR in patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR in patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin in patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel in patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53_mutated, but not TP53_wild_type, breast cancer xenotransplant mouse model (Ma et al., 2012; 22446188). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "R175H", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R175H"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). In the TCGA dataset, TP53 alterations have been reported in 35% of glioblastomas (GBMs), with a high incidence in pediatric and secondary GBMs and a low incidence in primary GBMs (Cancer Genome Atlas Research Network., 2008; 18772890, Jha et al., 2011; 22089350). One study detected TP53 alterations in 31% (73/232) of IDH_wildtype GBM samples analyzed, with most of the events being mutations (Yan et al. 2020; DOI:10.1200/PO.19.00385). TP53 mutations have been reported in 18_40% of astrocytoma samples, and preferentially in anaplastic astrocytoma; one study reported TP53 loss of function and partially/fully functional mutations in 15% and 25% of anaplastic astrocytomas, respectively (Uno et al., 2005; 15914282, Uno et al., 2006; 16711514, Lass et al., 2012; 22844452, Faria et al., 2012; 23009112, Milinkovic et al., 2013; 24358143, Galatro et al., 2013; 23613880). Some studies suggest that the presence of a TP53 mutation is correlated with a favorable prognosis in patients with glioblastoma (GBM) (Schmidt et al., 2002; 11939587). One study reported that TP53 alterations were associated with poorer OS (12.9 months altered vs. 19.7 months wildtype, HR=1.58, p=0.0054) in IDH_wildtype GBM (Yan et al. 2020; DOI:10.1200/PO.19.00385). Mutation of TP53 is thought to be an early step in the tumorigenesis of astrocytomas, which can progress into anaplastic astrocytoma and then glioblastoma through gain of other genetic abnormalities such as loss of CDKN2A or RB1, followed by loss of PTEN (Nozaki et al., 1999; 11550308). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) in patients with TP53 mutations versus 12.1% (4/33) in patients who were TP53 wild_type (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR in patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR in patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin in patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel in patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53_mutated, but not TP53_wild_type, breast cancer xenotransplant mouse model (Ma et al., 2012; 22446188). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "25", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "25"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB that may be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors in POLE_mutated glioma. Although efficacy of immune checkpoint inhibitors has been observed for patients with other solid tumor types harboring TMB levels such as seen here (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947), an association between TMB and clinical benefit has generally not been observed for patients with glioma (Touat et al., 2020; 32322066, Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254), except for those with ultramutated glioma with POLE mutation (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). Therefore, these agents may have efficacy for patients with this cancer type harboring both high TMB and POLE mutation. Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high_grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti_PD_1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti_PD_L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD_1 or PD_L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "KRAS", "Alteration": "V14I", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "V14I", "Title": "Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs", "Locations": "Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)", "NCTID": "NCT03284502", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "V14I", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "V14I", "Title": "Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "RAFs, EGFR, MEK", "Locations": "Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas", "NCTID": "NCT03905148", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "V14I", "Title": "A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)", "StudyPhase": "PHASE 1", "Target": "KRAS, SOS1, MEK", "Locations": "Frankfurt am Main (Germany), K\u00f6ln (Germany), Utrecht (Netherlands), Rotterdam (Netherlands), Massachusetts, Tennessee, Texas, North Carolina", "NCTID": "NCT04111458", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "V14I", "Title": "PF_07284892 in Participants With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "SHP2, ROS1, ALK, BRAF, EGFR, MEK", "Locations": "California, Michigan, New York, Tennessee, Texas", "NCTID": "NCT04800822", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "V14I", "Title": "Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Toronto (Canada)", "NCTID": "NCT02070549", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "V14I", "Title": "Phase I Trial of RO5126766", "StudyPhase": "PHASE 1", "Target": "RAFs, MEK, mTOR", "Locations": "London (United Kingdom), Sutton (United Kingdom)", "NCTID": "NCT02407509", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "V14I", "Title": "Selumetinib and Olaparib in Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, PARP", "Locations": "Texas", "NCTID": "NCT03162627", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "V14I", "Title": "Study of the Pan_ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation", "StudyPhase": "PHASE 1", "Target": "mTOR, EGFR, ERBB2, ERBB4, CDK4, CDK6, MEK", "Locations": "Texas", "NCTID": "NCT03065387", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "S340fs*12", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "S340fs*12", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "S340fs*12", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "S340fs*12", "Title": "Ph0/2 Ribociclib & Everolimus", "StudyPhase": "PHASE null", "Target": "CDK6, CDK4, mTOR", "Locations": "Arizona", "NCTID": "NCT03834740", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "S340fs*12", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "S340fs*12", "Title": "Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "RAFs, EGFR, MEK", "Locations": "Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas", "NCTID": "NCT03905148", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "S340fs*12", "Title": "NCT Neuro Master Match _ N\u00b2M\u00b2 (NOA_20)", "StudyPhase": "PHASE 1/2", "Target": "ALK, RET, CDK4, CDK6, mTOR, MDM2, PD_L1, SMO", "Locations": "Berlin (Germany), Dresden (Germany), Regensburg (Germany), Bochum (Germany), Frankfurt am Main (Germany), Essen (Germany), Mainz (Germany), Heidelberg (Germany), Cologne (Germany), Mannheim (Germany)", "NCTID": "NCT03158389", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "S340fs*12", "Title": "PF_07284892 in Participants With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "SHP2, ROS1, ALK, BRAF, EGFR, MEK", "Locations": "California, Michigan, New York, Tennessee, Texas", "NCTID": "NCT04800822", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "S340fs*12", "Title": "Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Toronto (Canada)", "NCTID": "NCT02070549", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "S340fs*12", "Title": "Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT03065062", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "S847L", "Title": "A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors", "StudyPhase": "PHASE 2", "Target": "BRAF, KIT, RET, VEGFRs, PD_1", "Locations": "Taipei (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Kobe (Japan), Nagoya (Japan), Chuo_ku (Japan), Koto_ku (Japan), Kita_Adachigun (Japan), Padova (Italy)", "NCTID": "NCT04704154", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "S847L", "Title": "A Phase II/III Study of High_dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme", "StudyPhase": "PHASE 2/3", "Target": "CSF1R, FLT3, KIT, RET, VEGFRs", "Locations": "Groningen (Netherlands), Nijmegen (Netherlands), Amsterdam (Netherlands)", "NCTID": "NCT03025893", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "S847L", "Title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma", "StudyPhase": "PHASE 2/3", "Target": "BRAF, KIT, RET, VEGFRs", "Locations": "Washington, Utah, California, Colorado, Minnesota, Wisconsin, Montr\u00e9al (Canada), Michigan", "NCTID": "NCT03970447", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "S847L", "Title": "Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma", "StudyPhase": "PHASE 2", "Target": "BRAF, KIT, RET, VEGFRs", "Locations": "Ohio", "NCTID": "NCT04051606", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "S847L", "Title": "A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRAF, KIT, RET, VEGFRs, PD_L1", "Locations": "Kurralta Park (Australia)", "NCTID": "NCT04200404", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "S847L", "Title": "Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors", "StudyPhase": "PHASE 1", "Target": "ABL, KIT", "Locations": "Maryland", "NCTID": "NCT02379416", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "S847L", "Title": "A Study of CS1003 in Subjects With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_1, BRAF, KIT, RET, VEGFRs", "Locations": "Randwick (Australia)", "NCTID": "NCT03475251", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "S847L", "Title": "Ipilimumab and Imatinib Mesylate in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "KIT, ABL, CTLA_4", "Locations": "Texas", "NCTID": "NCT01738139", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R233*", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R233*", "Title": "Talazoparib _ Carboplatin for Recurrent High_grade Glioma With DDRd", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Hong Kong (Hong Kong)", "NCTID": "NCT04740190", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R233*", "Title": "AZD8186 and Paclitaxel in Advanced Gastric Cancer", "StudyPhase": "PHASE 1/2", "Target": "PI3K_beta", "Locations": "Seongnam_si (Korea, Republic of)", "NCTID": "NCT04001569", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R233*", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California", "NCTID": "NCT02264678", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R233*", "Title": "Niraparib Combined With Radiotherapy in rGBM", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Tianjin (China)", "NCTID": "NCT04715620", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R233*", "Title": "STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS", "StudyPhase": "PHASE 1", "Target": "PARP", "Locations": "Beijing (China), Changchun (China)", "NCTID": "NCT04635631", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R233*", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R233*", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R233*", "Title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response", "StudyPhase": "PHASE 2", "Target": "ALK, ROS1, TRKA, TRKB, TRKC, PD_L1, ERBB2, ERBB3, PI3K_alpha, RET, AKTs", "Locations": "Alaska, Washington, Oregon, California, Montana", "NCTID": "NCT04632992", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R233*", "Title": "Study of RP_3500 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP", "Locations": "Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas", "NCTID": "NCT04497116", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RNF43", "Alteration": "G659fs*41", "Title": "A Study to Evaluate the Safety and Tolerability of ETC_1922159 in Advanced Solid Tumours", "StudyPhase": "PHASE 1", "Target": "PORCN", "Locations": "Singapore (Singapore), Colorado, Missouri, Texas, North Carolina", "NCTID": "NCT02521844", "Note": "Based on preclinical evidence, tumors with loss or inactivation of RNF43 may be sensitive to inhibitors of the WNT signaling pathway.", "Include": "true"}, {"Gene": "RNF43", "Alteration": "G659fs*41", "Title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands", "StudyPhase": "PHASE 1", "Target": "PORCN, PD_1", "Locations": "Utrecht (Netherlands), Rotterdam (Netherlands), Barcelona (Spain), Hospitalet de LLobregat (Spain), Valencia (Spain), Madrid (Spain), California, Michigan, Massachusetts, New York", "NCTID": "NCT01351103", "Note": "Based on preclinical evidence, tumors with loss or inactivation of RNF43 may be sensitive to inhibitors of the WNT signaling pathway.", "Include": "true"}, {"Gene": "RNF43", "Alteration": "G659fs*41", "Title": "Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies", "StudyPhase": "PHASE 1", "Target": "PORCN", "Locations": "Newcastle (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT03447470", "Note": "Based on preclinical evidence, tumors with loss or inactivation of RNF43 may be sensitive to inhibitors of the WNT signaling pathway.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "R1438Q", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "R1438Q", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "R1438Q", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "R1438Q", "Title": "Ph0/2 Ribociclib & Everolimus", "StudyPhase": "PHASE null", "Target": "CDK6, CDK4, mTOR", "Locations": "Arizona", "NCTID": "NCT03834740", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "R1438Q", "Title": "NCT Neuro Master Match _ N\u00b2M\u00b2 (NOA_20)", "StudyPhase": "PHASE 1/2", "Target": "ALK, RET, CDK4, CDK6, mTOR, MDM2, PD_L1, SMO", "Locations": "Berlin (Germany), Dresden (Germany), Regensburg (Germany), Bochum (Germany), Frankfurt am Main (Germany), Essen (Germany), Mainz (Germany), Heidelberg (Germany), Cologne (Germany), Mannheim (Germany)", "NCTID": "NCT03158389", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "R1438Q", "Title": "Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT03065062", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "R1438Q", "Title": "Sapanisertib and Ziv_Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "StudyPhase": "PHASE 1", "Target": "PIGF, VEGFA, VEGFB, mTORC1, mTORC2", "Locations": "Texas", "NCTID": "NCT02159989", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "R1438Q", "Title": "Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy", "StudyPhase": "PHASE 1", "Target": "IDO1, mTOR", "Locations": "Kansas", "NCTID": "NCT03217669", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "R1438Q", "Title": "Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and Other Indications", "StudyPhase": "PHASE 1", "Target": "VEGFA, HDAC, mTOR, EGFR", "Locations": "Texas", "NCTID": "NCT01552434", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "R1438Q", "Title": "A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "mTOR, EGFR, RET, SRC, VEGFRs", "Locations": "Texas", "NCTID": "NCT01582191", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "18313049", "FullCitation": "Sugiura T, et al. Exp. Cell Res. (2008) pmid: 18313049", "Include": "true"}, {"number": "1", "ReferenceId": "15492824", "FullCitation": "Yagyu R, et al. Int. J. Oncol. (2004) pmid: 15492824", "Include": "true"}, {"number": "2", "ReferenceId": "22575959", "FullCitation": "Hao HX, et al. Nature (2012) pmid: 22575959", "Include": "true"}, {"number": "3", "ReferenceId": "22895187", "FullCitation": "Koo BK, et al. Nature (2012) pmid: 22895187", "Include": "true"}, {"number": "4", "ReferenceId": "23847203", "FullCitation": "Jiang X, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23847203", "Include": "true"}, {"number": "5", "ReferenceId": "26023187", "FullCitation": "Koo BK, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 26023187", "Include": "true"}, {"number": "6", "ReferenceId": "25825523", "FullCitation": "Tsukiyama T, et al. Mol. Cell. Biol. (2015) pmid: 25825523", "Include": "true"}, {"number": "7", "ReferenceId": "21108931", "FullCitation": "Shinada K, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21108931", "Include": "true"}, {"number": "8", "ReferenceId": "23303603", "FullCitation": "Kinde I, et al. Sci Transl Med (2013) pmid: 23303603", "Include": "true"}, {"number": "9", "ReferenceId": "25344691", "FullCitation": "Giannakis M, et al. Nat. Genet. (2014) pmid: 25344691", "Include": "true"}, {"number": "10", "ReferenceId": "25901018", "FullCitation": "Madan B, et al. Mol. Cancer Ther. (2015) pmid: 25901018", "Include": "true"}, {"number": "11", "ReferenceId": "23096461", "FullCitation": "Ryland GL, et al. J. Pathol. (2013) pmid: 23096461", "Include": "true"}, {"number": "12", "ReferenceId": "22561520", "FullCitation": "Ong CK, et al. Nat. Genet. (2012) pmid: 22561520", "Include": "true"}, {"number": "13", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "14", "ReferenceId": "24816253", "FullCitation": "Wang K, et al. Nat. Genet. (2014) pmid: 24816253", "Include": "true"}, {"number": "15", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "16", "ReferenceId": "1904223", "FullCitation": "Hattori S, et al. Biochem. Biophys. Res. Commun. (1991) pmid: 1904223", "Include": "true"}, {"number": "17", "ReferenceId": "8628317", "FullCitation": "Morcos P, et al. Mol. Cell. Biol. (1996) pmid: 8628317", "Include": "true"}, {"number": "18", "ReferenceId": "2121371", "FullCitation": "Ballester R, et al. Cell (1990) pmid: 2121371", "Include": "true"}, {"number": "19", "ReferenceId": "2116237", "FullCitation": "Xu GF, et al. Cell (1990) pmid: 2116237", "Include": "true"}, {"number": "20", "ReferenceId": "2121370", "FullCitation": "Martin GA, et al. Cell (1990) pmid: 2121370", "Include": "true"}, {"number": "21", "ReferenceId": "22807134", "FullCitation": "Thomas L, et al. Hum. Mutat. (2012) pmid: 22807134", "Include": "true"}, {"number": "22", "ReferenceId": "9300663", "FullCitation": "Skuse GR, et al. Hum. Mol. Genet. (1997) pmid: 9300663", "Include": "true"}, {"number": "23", "ReferenceId": "11258625", "FullCitation": "Messiaen LM, et al. Genet. Med. () pmid: 11258625", "Include": "true"}, {"number": "24", "ReferenceId": "10607834", "FullCitation": "Ars E, et al. Hum. Mol. Genet. (2000) pmid: 10607834", "Include": "true"}, {"number": "25", "ReferenceId": "15863657", "FullCitation": "Messiaen LM, et al. J. Med. Genet. (2005) pmid: 15863657", "Include": "true"}, {"number": "26", "ReferenceId": "8264648", "FullCitation": "Poullet P, et al. Mol. Cell. Biol. (1994) pmid: 8264648", "Include": "true"}, {"number": "27", "ReferenceId": "26061751", "FullCitation": "Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751", "Include": "true"}, {"number": "28", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "29", "ReferenceId": "24120142", "FullCitation": "Brennan CW, et al. Cell (2013) pmid: 24120142", "Include": "true"}, {"number": "30", "ReferenceId": "18772890", "FullCitation": "Nature (2008) pmid: 18772890", "Include": "true"}, {"number": "31", "ReferenceId": "20129251", "FullCitation": "Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251", "Include": "true"}, {"number": "32", "ReferenceId": "26190195", "FullCitation": "Vizca\u00edno MA, et al. Hum. Pathol. (2015) pmid: 26190195", "Include": "true"}, {"number": "33", "ReferenceId": "28029918", "FullCitation": "Dombi E, et al. N. Engl. J. Med. (2016) pmid: 28029918", "Include": "true"}, {"number": "34", "ReferenceId": "33903938", "FullCitation": "Schalkwijk S, et al. Cancer Chemother Pharmacol (2021) pmid: 33903938", "Include": "true"}, {"number": "35", "ReferenceId": "33751171", "FullCitation": "Toledano H, et al. Childs Nerv Syst (2021) pmid: 33751171", "Include": "true"}, {"number": "36", "ReferenceId": "33939292", "FullCitation": "Ronsley R, et al. Cancer Med (2021) pmid: 33939292", "Include": "true"}, {"number": "37", "ReferenceId": "31151904", "FullCitation": "Fangusaro J, et al. Lancet Oncol. (2019) pmid: 31151904", "Include": "true"}, {"number": "38", "ReferenceId": "32780261", "FullCitation": "Manoharan N, et al. J Neurooncol (2020) pmid: 32780261", "Include": "true"}, {"number": "39", "ReferenceId": "30097824", "FullCitation": "Kondyli M, et al. J Neurooncol (2018) pmid: 30097824", "Include": "true"}, {"number": "40", "ReferenceId": "33082744", "FullCitation": "Awada G, et al. Case Rep Oncol () pmid: 33082744", "Include": "true"}, {"number": "41", "ReferenceId": "32669708", "FullCitation": "Middleton G, et al. Nature (2020) pmid: 32669708", "Include": "true"}, {"number": "42", "ReferenceId": "26859683", "FullCitation": "Lim SM, et al. Oncotarget (2016) pmid: 26859683", "Include": "true"}, {"number": "43", "ReferenceId": "25314964", "FullCitation": "Weiss B, et al. Neuro_oncology (2015) pmid: 25314964", "Include": "true"}, {"number": "44", "ReferenceId": "24931142", "FullCitation": "Janku F, et al. Oncotarget (2014) pmid: 24931142", "Include": "true"}, {"number": "45", "ReferenceId": "18164202", "FullCitation": "Johannessen CM, et al. Curr. Biol. (2008) pmid: 18164202", "Include": "true"}, {"number": "46", "ReferenceId": "15937108", "FullCitation": "Johannessen CM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15937108", "Include": "true"}, {"number": "47", "ReferenceId": "24913553", "FullCitation": "Malone CF, et al. Cancer Discov (2014) pmid: 24913553", "Include": "true"}, {"number": "48", "ReferenceId": "25344362", "FullCitation": "Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362", "Include": "true"}, {"number": "49", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "50", "ReferenceId": "20027112", "FullCitation": "Jett K, et al. Genet. Med. (2010) pmid: 20027112", "Include": "true"}, {"number": "51", "ReferenceId": "22240541", "FullCitation": "Patil S, et al. Oncologist (2012) pmid: 22240541", "Include": "true"}, {"number": "52", "ReferenceId": "23036231", "FullCitation": "Evans DG, et al. Clin Sarcoma Res (2012) pmid: 23036231", "Include": "true"}, {"number": "53", "ReferenceId": "8544190", "FullCitation": "Upadhyaya M, et al. J. Med. Genet. (1995) pmid: 8544190", "Include": "true"}, {"number": "54", "ReferenceId": "19117870", "FullCitation": "Williams VC, et al. Pediatrics (2009) pmid: 19117870", "Include": "true"}, {"number": "55", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "56", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "57", "ReferenceId": "20949621", "FullCitation": "Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621", "Include": "true"}, {"number": "58", "ReferenceId": "14534542", "FullCitation": "Lee SH, et al. Oncogene (2003) pmid: 14534542", "Include": "true"}, {"number": "59", "ReferenceId": "16474405", "FullCitation": "Schubbert S, et al. Nat. Genet. (2006) pmid: 16474405", "Include": "true"}, {"number": "60", "ReferenceId": "17875937", "FullCitation": "Schubbert S, et al. Mol. Cell. Biol. (2007) pmid: 17875937", "Include": "true"}, {"number": "61", "ReferenceId": "18247425", "FullCitation": "Gripp KW, et al. Am. J. Med. Genet. A (2008) pmid: 18247425", "Include": "true"}, {"number": "62", "ReferenceId": "17211612", "FullCitation": "Kratz CP, et al. J. Mol. Med. (2007) pmid: 17211612", "Include": "true"}, {"number": "63", "ReferenceId": "23059812", "FullCitation": "Cirstea IC, et al. Hum. Mol. Genet. (2013) pmid: 23059812", "Include": "true"}, {"number": "64", "ReferenceId": "21797849", "FullCitation": "Stark Z, et al. Clin. Genet. (2012) pmid: 21797849", "Include": "true"}, {"number": "65", "ReferenceId": "21424530", "FullCitation": "Cin H, et al. Acta Neuropathol. (2011) pmid: 21424530", "Include": "true"}, {"number": "66", "ReferenceId": "17712732", "FullCitation": "Janzarik WG, et al. Neuropediatrics (2007) pmid: 17712732", "Include": "true"}, {"number": "67", "ReferenceId": "15517309", "FullCitation": "Knobbe CB, et al. Acta Neuropathol. (2004) pmid: 15517309", "Include": "true"}, {"number": "68", "ReferenceId": "22015553", "FullCitation": "Mellinghoff IK, et al. Curr. Top. Microbiol. Immunol. (2012) pmid: 22015553", "Include": "true"}, {"number": "69", "ReferenceId": "10802656", "FullCitation": "Holland EC, et al. Nat. Genet. (2000) pmid: 10802656", "Include": "true"}, {"number": "70", "ReferenceId": "16166301", "FullCitation": "Holmen SL, et al. Cancer Res. (2005) pmid: 16166301", "Include": "true"}, {"number": "71", "ReferenceId": "31068384", "FullCitation": "Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384", "Include": "true"}, {"number": "72", "ReferenceId": "29808006", "FullCitation": "Mainardi S, et al. Nat Med (2018) pmid: 29808006", "Include": "true"}, {"number": "73", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "74", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "75", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "76", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "77", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "78", "ReferenceId": "32822286", "FullCitation": "Monk BJ, et al. J Clin Oncol (2020) pmid: 32822286", "Include": "true"}, {"number": "79", "ReferenceId": "23261356", "FullCitation": "Farley J, et al. Lancet Oncol. (2013) pmid: 23261356", "Include": "true"}, {"number": "80", "ReferenceId": "29765547", "FullCitation": "Slosberg ED, et al. Oncotarget (2018) pmid: 29765547", "Include": "true"}, {"number": "81", "ReferenceId": "29946554", "FullCitation": "Han C, et al. Gynecol Oncol Rep (2018) pmid: 29946554", "Include": "true"}, {"number": "82", "ReferenceId": "26075998", "FullCitation": "Lyons YA, et al. Gynecol Oncol Rep (2014) pmid: 26075998", "Include": "true"}, {"number": "83", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "84", "ReferenceId": "24947927", "FullCitation": "Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927", "Include": "true"}, {"number": "85", "ReferenceId": "20127139", "FullCitation": "Bennouna J, et al. Invest New Drugs (2011) pmid: 20127139", "Include": "true"}, {"number": "86", "ReferenceId": "23434733", "FullCitation": "Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733", "Include": "true"}, {"number": "87", "ReferenceId": "27975152", "FullCitation": "Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152", "Include": "true"}, {"number": "88", "ReferenceId": "24915778", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778", "Include": "true"}, {"number": "89", "ReferenceId": "29756206", "FullCitation": "Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206", "Include": "true"}, {"number": "90", "ReferenceId": "25722381", "FullCitation": "Blumenschein GR, et al. Ann. Oncol. (2015) pmid: 25722381", "Include": "true"}, {"number": "91", "ReferenceId": "22767668", "FullCitation": "Leijen S, et al. Clin. Cancer Res. (2012) pmid: 22767668", "Include": "true"}, {"number": "92", "ReferenceId": "31118140", "FullCitation": "Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31118140", "Include": "true"}, {"number": "93", "ReferenceId": "31020608", "FullCitation": "Shapiro GI, et al. Invest New Drugs (2019) pmid: 31020608", "Include": "true"}, {"number": "94", "ReferenceId": "11237521", "FullCitation": "Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521", "Include": "true"}, {"number": "95", "ReferenceId": "12857747", "FullCitation": "Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747", "Include": "true"}, {"number": "96", "ReferenceId": "21828076", "FullCitation": "Rodr\u00edguez_Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076", "Include": "true"}, {"number": "97", "ReferenceId": "23475934", "FullCitation": "He X, et al. Cancer Res. (2013) pmid: 23475934", "Include": "true"}, {"number": "98", "ReferenceId": "10866302", "FullCitation": "Han SY, et al. Cancer Res. (2000) pmid: 10866302", "Include": "true"}, {"number": "99", "ReferenceId": "9811831", "FullCitation": "Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831", "Include": "true"}, {"number": "100", "ReferenceId": "24498881", "FullCitation": "Pradella LM, et al. BMC Cancer (2014) pmid: 24498881", "Include": "true"}, {"number": "101", "ReferenceId": "21536651", "FullCitation": "Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651", "Include": "true"}, {"number": "102", "ReferenceId": "17213812", "FullCitation": "Denning G, et al. Oncogene (2007) pmid: 17213812", "Include": "true"}, {"number": "103", "ReferenceId": "16619501", "FullCitation": "Hlobilkova A, et al. Anticancer Res. () pmid: 16619501", "Include": "true"}, {"number": "104", "ReferenceId": "20718038", "FullCitation": "Redfern RE, et al. Protein Sci. (2010) pmid: 20718038", "Include": "true"}, {"number": "105", "ReferenceId": "22505997", "FullCitation": "Shenoy S, et al. PLoS ONE (2012) pmid: 22505997", "Include": "true"}, {"number": "106", "ReferenceId": "19329485", "FullCitation": "Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485", "Include": "true"}, {"number": "107", "ReferenceId": "16829519", "FullCitation": "Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519", "Include": "true"}, {"number": "108", "ReferenceId": "10555148", "FullCitation": "Lee JO, et al. Cell (1999) pmid: 10555148", "Include": "true"}, {"number": "109", "ReferenceId": "9635567", "FullCitation": "Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567", "Include": "true"}, {"number": "110", "ReferenceId": "9865913", "FullCitation": "Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913", "Include": "true"}, {"number": "111", "ReferenceId": "11051241", "FullCitation": "Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241", "Include": "true"}, {"number": "112", "ReferenceId": "22891331", "FullCitation": "Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331", "Include": "true"}, {"number": "113", "ReferenceId": "23066114", "FullCitation": "Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114", "Include": "true"}, {"number": "114", "ReferenceId": "19457929", "FullCitation": "Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929", "Include": "true"}, {"number": "115", "ReferenceId": "23995781", "FullCitation": "Liu J, et al. Oncogene (2014) pmid: 23995781", "Include": "true"}, {"number": "116", "ReferenceId": "11395408", "FullCitation": "Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408", "Include": "true"}, {"number": "117", "ReferenceId": "10807691", "FullCitation": "De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691", "Include": "true"}, {"number": "118", "ReferenceId": "10051603", "FullCitation": "Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603", "Include": "true"}, {"number": "119", "ReferenceId": "15988030", "FullCitation": "Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030", "Include": "true"}, {"number": "120", "ReferenceId": "15026806", "FullCitation": "Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806", "Include": "true"}, {"number": "121", "ReferenceId": "25875300", "FullCitation": "Gil A, et al. PLoS ONE (2015) pmid: 25875300", "Include": "true"}, {"number": "122", "ReferenceId": "9823298", "FullCitation": "Furnari FB, et al. Cancer Res. (1998) pmid: 9823298", "Include": "true"}, {"number": "123", "ReferenceId": "25527629", "FullCitation": "Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629", "Include": "true"}, {"number": "124", "ReferenceId": "29706633", "FullCitation": "Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633", "Include": "true"}, {"number": "125", "ReferenceId": "20538496", "FullCitation": "Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496", "Include": "true"}, {"number": "126", "ReferenceId": "17942903", "FullCitation": "Andr\u00e9s_Pons A, et al. Cancer Res. (2007) pmid: 17942903", "Include": "true"}, {"number": "127", "ReferenceId": "15805158", "FullCitation": "Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158", "Include": "true"}, {"number": "128", "ReferenceId": "10468583", "FullCitation": "Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583", "Include": "true"}, {"number": "129", "ReferenceId": "12085208", "FullCitation": "Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208", "Include": "true"}, {"number": "130", "ReferenceId": "24292679", "FullCitation": "Nguyen HN, et al. Oncogene (2014) pmid: 24292679", "Include": "true"}, {"number": "131", "ReferenceId": "19114656", "FullCitation": "Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656", "Include": "true"}, {"number": "132", "ReferenceId": "12808147", "FullCitation": "Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147", "Include": "true"}, {"number": "133", "ReferenceId": "18498243", "FullCitation": "Wang X, et al. Biochem. J. (2008) pmid: 18498243", "Include": "true"}, {"number": "134", "ReferenceId": "15951562", "FullCitation": "Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562", "Include": "true"}, {"number": "135", "ReferenceId": "25263454", "FullCitation": "Nguyen HN, et al. Oncogene (2015) pmid: 25263454", "Include": "true"}, {"number": "136", "ReferenceId": "10096247", "FullCitation": "Zhou XP, et al. Int. J. Cancer (1999) pmid: 10096247", "Include": "true"}, {"number": "137", "ReferenceId": "9331072", "FullCitation": "Rasheed BK, et al. Cancer Res. (1997) pmid: 9331072", "Include": "true"}, {"number": "138", "ReferenceId": "10188904", "FullCitation": "Davies MP, et al. Br. J. Cancer (1999) pmid: 10188904", "Include": "true"}, {"number": "139", "ReferenceId": "11504770", "FullCitation": "Smith JS, et al. J. Natl. Cancer Inst. (2001) pmid: 11504770", "Include": "true"}, {"number": "140", "ReferenceId": "9796977", "FullCitation": "Lin H, et al. Clin. Cancer Res. (1998) pmid: 9796977", "Include": "true"}, {"number": "141", "ReferenceId": "10560660", "FullCitation": "Schmidt EE, et al. J. Neuropathol. Exp. Neurol. (1999) pmid: 10560660", "Include": "true"}, {"number": "142", "ReferenceId": "17974913", "FullCitation": "Furnari FB, et al. Genes Dev. (2007) pmid: 17974913", "Include": "true"}, {"number": "143", "ReferenceId": "10213484", "FullCitation": "Sano T, et al. Cancer Res. (1999) pmid: 10213484", "Include": "true"}, {"number": "144", "ReferenceId": "21134002", "FullCitation": "Srividya MR, et al. Neuropathology (2011) pmid: 21134002", "Include": "true"}, {"number": "145", "ReferenceId": "20085938", "FullCitation": "Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938", "Include": "true"}, {"number": "146", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "147", "ReferenceId": "28220839", "FullCitation": "Milella M, et al. Sci Rep (2017) pmid: 28220839", "Include": "true"}, {"number": "148", "ReferenceId": "15998902", "FullCitation": "Galanis E, et al. J. Clin. Oncol. (2005) pmid: 15998902", "Include": "true"}, {"number": "149", "ReferenceId": "19018475", "FullCitation": "Kreisl TN, et al. J. Neurooncol. (2009) pmid: 19018475", "Include": "true"}, {"number": "150", "ReferenceId": "22160854", "FullCitation": "Mason WP, et al. Invest New Drugs (2012) pmid: 22160854", "Include": "true"}, {"number": "151", "ReferenceId": "20049735", "FullCitation": "Mendes_Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735", "Include": "true"}, {"number": "152", "ReferenceId": "23881923", "FullCitation": "Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923", "Include": "true"}, {"number": "153", "ReferenceId": "23565244", "FullCitation": "Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244", "Include": "true"}, {"number": "154", "ReferenceId": "26905328", "FullCitation": "McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328", "Include": "true"}, {"number": "155", "ReferenceId": "21468130", "FullCitation": "Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130", "Include": "true"}, {"number": "156", "ReferenceId": "33242536", "FullCitation": "Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536", "Include": "true"}, {"number": "157", "ReferenceId": "33970096", "FullCitation": "Pan M, et al. Perm J (2021) pmid: 33970096", "Include": "true"}, {"number": "158", "ReferenceId": "23810788", "FullCitation": "Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788", "Include": "true"}, {"number": "159", "ReferenceId": "32988624", "FullCitation": "Romero I, et al. Gynecol Oncol (2020) pmid: 32988624", "Include": "true"}, {"number": "160", "ReferenceId": "31594766", "FullCitation": "Costa C, et al. Cancer Discov (2019) pmid: 31594766", "Include": "true"}, {"number": "161", "ReferenceId": "30742119", "FullCitation": "Zhao J, et al. Nat. Med. (2019) pmid: 30742119", "Include": "true"}, {"number": "162", "ReferenceId": "28228279", "FullCitation": "George S, et al. Immunity (2017) pmid: 28228279", "Include": "true"}, {"number": "163", "ReferenceId": "26645196", "FullCitation": "Peng W, et al. Cancer Discov (2016) pmid: 26645196", "Include": "true"}, {"number": "164", "ReferenceId": "18781191", "FullCitation": "Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191", "Include": "true"}, {"number": "165", "ReferenceId": "18794875", "FullCitation": "Orloff MS, et al. Oncogene (2008) pmid: 18794875", "Include": "true"}, {"number": "166", "ReferenceId": "17167516", "FullCitation": "Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516", "Include": "true"}, {"number": "167", "ReferenceId": "18483217", "FullCitation": "Andrae J, et al. Genes Dev. (2008) pmid: 18483217", "Include": "true"}, {"number": "168", "ReferenceId": "15175998", "FullCitation": "Semin. Oncol. (2004) pmid: 15175998", "Include": "true"}, {"number": "169", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "170", "ReferenceId": "29625048", "FullCitation": "Hoadley KA, et al. Cell (2018) pmid: 29625048", "Include": "true"}, {"number": "171", "ReferenceId": "29596782", "FullCitation": "Ellrott K, et al. Cell Syst (2018) pmid: 29596782", "Include": "true"}, {"number": "172", "ReferenceId": "29622463", "FullCitation": "Taylor AM, et al. Cancer Cell (2018) pmid: 29622463", "Include": "true"}, {"number": "173", "ReferenceId": "29617662", "FullCitation": "Gao Q, et al. Cell Rep (2018) pmid: 29617662", "Include": "true"}, {"number": "174", "ReferenceId": "29625055", "FullCitation": "Liu J, et al. Cell (2018) pmid: 29625055", "Include": "true"}, {"number": "175", "ReferenceId": "29625050", "FullCitation": "Sanchez_Vega F, et al. Cell (2018) pmid: 29625050", "Include": "true"}, {"number": "176", "ReferenceId": "29888103", "FullCitation": "Song K, et al. Am J Cancer Res (2018) pmid: 29888103", "Include": "true"}, {"number": "177", "ReferenceId": "23074200", "FullCitation": "Alentorn A, et al. Neuro_oncology (2012) pmid: 23074200", "Include": "true"}, {"number": "178", "ReferenceId": "23412337", "FullCitation": "Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337", "Include": "true"}, {"number": "179", "ReferenceId": "23438035", "FullCitation": "Phillips JJ, et al. Brain Pathol. (2013) pmid: 23438035", "Include": "true"}, {"number": "180", "ReferenceId": "22806436", "FullCitation": "Arefi M, et al. Int. J. Hematol. (2012) pmid: 22806436", "Include": "true"}, {"number": "181", "ReferenceId": "17666373", "FullCitation": "Baccarani M, et al. Haematologica (2007) pmid: 17666373", "Include": "true"}, {"number": "182", "ReferenceId": "22718859", "FullCitation": "Cassier PA, et al. Clin. Cancer Res. (2012) pmid: 22718859", "Include": "true"}, {"number": "183", "ReferenceId": "25658984", "FullCitation": "Chalmers ZR, et al. Blood Cancer J (2015) pmid: 25658984", "Include": "true"}, {"number": "184", "ReferenceId": "12660384", "FullCitation": "Cools J, et al. N. Engl. J. Med. (2003) pmid: 12660384", "Include": "true"}, {"number": "185", "ReferenceId": "17555450", "FullCitation": "Curtis CE, et al. Br. J. Haematol. (2007) pmid: 17555450", "Include": "true"}, {"number": "186", "ReferenceId": "15010069", "FullCitation": "Debiec_Rychter M, et al. Eur. J. Cancer (2004) pmid: 15010069", "Include": "true"}, {"number": "187", "ReferenceId": "20473908", "FullCitation": "Dileo P, et al. Int. J. Cancer (2011) pmid: 20473908", "Include": "true"}, {"number": "188", "ReferenceId": "24638008", "FullCitation": "Fanta PT, et al. J. Clin. Oncol. (2015) pmid: 24638008", "Include": "true"}, {"number": "189", "ReferenceId": "16406018", "FullCitation": "Florian S, et al. Leuk. Res. (2006) pmid: 16406018", "Include": "true"}, {"number": "190", "ReferenceId": "27051816", "FullCitation": "Frenard C, et al. JAAD Case Rep (2016) pmid: 27051816", "Include": "true"}, {"number": "191", "ReferenceId": "12808148", "FullCitation": "Griffin JH, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808148", "Include": "true"}, {"number": "192", "ReferenceId": "14645423", "FullCitation": "Heinrich MC, et al. J. Clin. Oncol. (2003) pmid: 14645423", "Include": "true"}, {"number": "193", "ReferenceId": "19120352", "FullCitation": "Helbig G, et al. Br. J. Haematol. (2009) pmid: 19120352", "Include": "true"}, {"number": "194", "ReferenceId": "24009127", "FullCitation": "Helbig G, et al. Am. J. Hematol. (2014) pmid: 24009127", "Include": "true"}, {"number": "195", "ReferenceId": "21093052", "FullCitation": "Hus M, et al. Leuk. Res. (2011) pmid: 21093052", "Include": "true"}, {"number": "196", "ReferenceId": "20303172", "FullCitation": "Ikezoe T, et al. Leuk. Res. (2010) pmid: 20303172", "Include": "true"}, {"number": "197", "ReferenceId": "19735261", "FullCitation": "Intermesoli T, et al. Br. J. Haematol. (2009) pmid: 19735261", "Include": "true"}, {"number": "198", "ReferenceId": "19013640", "FullCitation": "Jain N, et al. Leuk. Res. (2009) pmid: 19013640", "Include": "true"}, {"number": "199", "ReferenceId": "17299092", "FullCitation": "Jovanovic JV, et al. Blood (2007) pmid: 17299092", "Include": "true"}, {"number": "200", "ReferenceId": "22150077", "FullCitation": "Kang HJ, et al. Acta Oncol (2012) pmid: 22150077", "Include": "true"}, {"number": "201", "ReferenceId": "14504092", "FullCitation": "Klion AD, et al. Blood (2004) pmid: 14504092", "Include": "true"}, {"number": "202", "ReferenceId": "19192229", "FullCitation": "Kobayashi M, et al. Respirology (2009) pmid: 19192229", "Include": "true"}, {"number": "203", "ReferenceId": "24635438", "FullCitation": "Koc\u00e1kov\u00e1 I, et al. Klin Onkol (2014) pmid: 24635438", "Include": "true"}, {"number": "204", "ReferenceId": "18950453", "FullCitation": "Metzgeroth G, et al. Br. J. Haematol. (2008) pmid: 18950453", "Include": "true"}, {"number": "205", "ReferenceId": "22645636", "FullCitation": "Murayama Y, et al. World J Gastrointest Oncol (2012) pmid: 22645636", "Include": "true"}, {"number": "206", "ReferenceId": "19910029", "FullCitation": "Ogbogu PU, et al. J. Allergy Clin. Immunol. (2009) pmid: 19910029", "Include": "true"}, {"number": "207", "ReferenceId": "16856885", "FullCitation": "Ohnishi H, et al. Br. J. Haematol. (2006) pmid: 16856885", "Include": "true"}, {"number": "208", "ReferenceId": "12842979", "FullCitation": "Pardanani A, et al. Blood (2003) pmid: 12842979", "Include": "true"}, {"number": "209", "ReferenceId": "15284118", "FullCitation": "Pardanani A, et al. Blood (2004) pmid: 15284118", "Include": "true"}, {"number": "210", "ReferenceId": "27120808", "FullCitation": "Qu SQ, et al. Oncotarget (2016) pmid: 27120808", "Include": "true"}, {"number": "211", "ReferenceId": "16498388", "FullCitation": "Score J, et al. Leukemia (2006) pmid: 16498388", "Include": "true"}, {"number": "212", "ReferenceId": "24669761", "FullCitation": "Shah S, et al. J Hematol Oncol (2014) pmid: 24669761", "Include": "true"}, {"number": "213", "ReferenceId": "26319757", "FullCitation": "Sugimoto Y, et al. Cancer Genet (2015) pmid: 26319757", "Include": "true"}, {"number": "214", "ReferenceId": "20609486", "FullCitation": "Volz HC, et al. Int. J. Cardiol. (2011) pmid: 20609486", "Include": "true"}, {"number": "215", "ReferenceId": "15618966", "FullCitation": "von Bubnoff N, et al. Leukemia (2005) pmid: 15618966", "Include": "true"}, {"number": "216", "ReferenceId": "16845659", "FullCitation": "Walz C, et al. Genes Chromosomes Cancer (2006) pmid: 16845659", "Include": "true"}, {"number": "217", "ReferenceId": "26130666", "FullCitation": "Yoo C, et al. Cancer Res Treat (2016) pmid: 26130666", "Include": "true"}, {"number": "218", "ReferenceId": "23157309", "FullCitation": "Al_Riyami AZ, et al. Leuk. Lymphoma (2013) pmid: 23157309", "Include": "true"}, {"number": "219", "ReferenceId": "16645167", "FullCitation": "Lierman E, et al. Blood (2006) pmid: 16645167", "Include": "true"}, {"number": "220", "ReferenceId": "19212337", "FullCitation": "Lierman E, et al. Leukemia (2009) pmid: 19212337", "Include": "true"}, {"number": "221", "ReferenceId": "21818111", "FullCitation": "Metzgeroth G, et al. Leukemia (2012) pmid: 21818111", "Include": "true"}, {"number": "222", "ReferenceId": "22294526", "FullCitation": "Roubaud G, et al. Ann. Oncol. (2012) pmid: 22294526", "Include": "true"}, {"number": "223", "ReferenceId": "20972453", "FullCitation": "von Bubnoff N, et al. Oncogene (2011) pmid: 20972453", "Include": "true"}, {"number": "224", "ReferenceId": "24057647", "FullCitation": "Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2013) pmid: 24057647", "Include": "true"}, {"number": "225", "ReferenceId": "20832858", "FullCitation": "Tabouret E, et al. Leuk. Res. (2011) pmid: 20832858", "Include": "true"}, {"number": "226", "ReferenceId": "18794084", "FullCitation": "Dewaele B, et al. Clin. Cancer Res. (2008) pmid: 18794084", "Include": "true"}, {"number": "227", "ReferenceId": "17087936", "FullCitation": "Weisberg E, et al. Gastroenterology (2006) pmid: 17087936", "Include": "true"}, {"number": "228", "ReferenceId": "26396737", "FullCitation": "Brohl AS, et al. Clin Sarcoma Res (2015) pmid: 26396737", "Include": "true"}, {"number": "229", "ReferenceId": "28031906", "FullCitation": "Grellety T, et al. Future Sci OA (2015) pmid: 28031906", "Include": "true"}, {"number": "230", "ReferenceId": "25905001", "FullCitation": "Koll\u00e0r A, et al. Clin Sarcoma Res (2014) pmid: 25905001", "Include": "true"}, {"number": "231", "ReferenceId": "29093181", "FullCitation": "Evans EK, et al. Sci Transl Med (2017) pmid: 29093181", "Include": "true"}, {"number": "232", "ReferenceId": "12869586", "FullCitation": "Inoki K, et al. Genes Dev. (2003) pmid: 12869586", "Include": "true"}, {"number": "233", "ReferenceId": "12906785", "FullCitation": "Tee AR, et al. Curr. Biol. (2003) pmid: 12906785", "Include": "true"}, {"number": "234", "ReferenceId": "11129334", "FullCitation": "Parry L, et al. Hum. Genet. (2000) pmid: 11129334", "Include": "true"}, {"number": "235", "ReferenceId": "12469204", "FullCitation": "Lau N, et al. Int. J. Oncol. (2003) pmid: 12469204", "Include": "true"}, {"number": "236", "ReferenceId": "19286253", "FullCitation": "Rosner M, et al. Leuk. Res. (2009) pmid: 19286253", "Include": "true"}, {"number": "237", "ReferenceId": "16740698", "FullCitation": "Riemenschneider MJ, et al. Cancer Res. (2006) pmid: 16740698", "Include": "true"}, {"number": "238", "ReferenceId": "33575875", "FullCitation": "Mallela K, et al. Mol Cell Biochem (2021) pmid: 33575875", "Include": "true"}, {"number": "239", "ReferenceId": "25782670", "FullCitation": "Kwiatkowski DJ, et al. Eur J Hum Genet (2015) pmid: 25782670", "Include": "true"}, {"number": "240", "ReferenceId": "31597506", "FullCitation": "Wang T, et al. Cancer Biol Ther (2020) pmid: 31597506", "Include": "true"}, {"number": "241", "ReferenceId": "33575217", "FullCitation": "Guo G, et al. Front Oncol (2020) pmid: 33575217", "Include": "true"}, {"number": "242", "ReferenceId": "29764404", "FullCitation": "Espinosa M, et al. BMC Cancer (2018) pmid: 29764404", "Include": "true"}, {"number": "243", "ReferenceId": "28547571", "FullCitation": "Chuang CK, et al. Int Urol Nephrol (2017) pmid: 28547571", "Include": "true"}, {"number": "244", "ReferenceId": "33727259", "FullCitation": "Adib E, et al. Clin Cancer Res (2021) pmid: 33727259", "Include": "true"}, {"number": "245", "ReferenceId": "31653662", "FullCitation": "Nassar AH, et al. Mol Cancer Ther (2020) pmid: 31653662", "Include": "true"}, {"number": "246", "ReferenceId": "3032730", "FullCitation": "De S, et al. Gegenbaurs Morphol Jahrb (1986) pmid: 3032730", "Include": "true"}, {"number": "247", "ReferenceId": "20048174", "FullCitation": "Wagner AJ, et al. J. Clin. Oncol. (2010) pmid: 20048174", "Include": "true"}, {"number": "248", "ReferenceId": "22927055", "FullCitation": "Dickson MA, et al. Int. J. Cancer (2013) pmid: 22927055", "Include": "true"}, {"number": "249", "ReferenceId": "25295501", "FullCitation": "Wagle N, et al. N. Engl. J. Med. (2014) pmid: 25295501", "Include": "true"}, {"number": "250", "ReferenceId": "26626617", "FullCitation": "Tannir NM, et al. Eur. Urol. (2016) pmid: 26626617", "Include": "true"}, {"number": "251", "ReferenceId": "29632054", "FullCitation": "Maroto P, et al. J Natl Compr Canc Netw (2018) pmid: 29632054", "Include": "true"}, {"number": "252", "ReferenceId": "31154346", "FullCitation": "Zureick AH, et al. BMJ Case Rep (2019) pmid: 31154346", "Include": "true"}, {"number": "253", "ReferenceId": "33344249", "FullCitation": "Hu W, et al. Front Oncol (2020) pmid: 33344249", "Include": "true"}, {"number": "254", "ReferenceId": "27176796", "FullCitation": "Perini GF, et al. Blood Cancer J (2016) pmid: 27176796", "Include": "true"}, {"number": "255", "ReferenceId": "30327302", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302", "Include": "true"}, {"number": "256", "ReferenceId": "2039135", "FullCitation": "Ann. N. Y. Acad. Sci. (1991) pmid: 2039135", "Include": "true"}, {"number": "257", "ReferenceId": "1303246", "FullCitation": "Kandt RS, et al. Nat. Genet. (1992) pmid: 1303246", "Include": "true"}, {"number": "258", "ReferenceId": "8269512", "FullCitation": "Cell (1993) pmid: 8269512", "Include": "true"}, {"number": "259", "ReferenceId": "18722871", "FullCitation": "Curatolo P, et al. Lancet (2008) pmid: 18722871", "Include": "true"}, {"number": "260", "ReferenceId": "28659377", "FullCitation": "EMBO J. (2017) pmid: 28659377", "Include": "true"}, {"number": "261", "ReferenceId": "22941649", "FullCitation": "McNeil EM, et al. Nucleic Acids Res. (2012) pmid: 22941649", "Include": "true"}, {"number": "262", "ReferenceId": "25634215", "FullCitation": "Ceccaldi R, et al. Cancer Res. (2015) pmid: 25634215", "Include": "true"}, {"number": "263", "ReferenceId": "25965342", "FullCitation": "Mohni KN, et al. PLoS ONE (2015) pmid: 25965342", "Include": "true"}, {"number": "264", "ReferenceId": "26074087", "FullCitation": "Manandhar M, et al. Gene (2015) pmid: 26074087", "Include": "true"}, {"number": "265", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "266", "ReferenceId": "19297315", "FullCitation": "Planchard D, et al. Ann. Oncol. (2009) pmid: 19297315", "Include": "true"}, {"number": "267", "ReferenceId": "15764785", "FullCitation": "Simon GR, et al. Chest (2005) pmid: 15764785", "Include": "true"}, {"number": "268", "ReferenceId": "16957145", "FullCitation": "Olaussen KA, et al. N. Engl. J. Med. (2006) pmid: 16957145", "Include": "true"}, {"number": "269", "ReferenceId": "18594541", "FullCitation": "Jun HJ, et al. Br. J. Cancer (2008) pmid: 18594541", "Include": "true"}, {"number": "270", "ReferenceId": "17229776", "FullCitation": "Bellmunt J, et al. Ann. Oncol. (2007) pmid: 17229776", "Include": "true"}, {"number": "271", "ReferenceId": "11008124", "FullCitation": "Ferry KV, et al. Biochem. Pharmacol. (2000) pmid: 11008124", "Include": "true"}, {"number": "272", "ReferenceId": "21227924", "FullCitation": "Zhang YW, et al. Nucleic Acids Res. (2011) pmid: 21227924", "Include": "true"}, {"number": "273", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "274", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "275", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "276", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "277", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "278", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "279", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "280", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "281", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "282", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "283", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "284", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "285", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "286", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "287", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "288", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "289", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "290", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "291", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "292", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "293", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "294", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "295", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "296", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "297", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "298", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "299", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "300", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "301", "ReferenceId": "26824661", "FullCitation": "Ceccarelli M, et al. Cell (2016) pmid: 26824661", "Include": "true"}, {"number": "302", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "303", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "304", "ReferenceId": "16909113", "FullCitation": "Weber RG, et al. Oncogene (2007) pmid: 16909113", "Include": "true"}, {"number": "305", "ReferenceId": "11303791", "FullCitation": "Nakamura M, et al. Brain Pathol. (2001) pmid: 11303791", "Include": "true"}, {"number": "306", "ReferenceId": "11489817", "FullCitation": "Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817", "Include": "true"}, {"number": "307", "ReferenceId": "21713760", "FullCitation": "Feng J, et al. Cancer (2012) pmid: 21713760", "Include": "true"}, {"number": "308", "ReferenceId": "21636552", "FullCitation": "Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552", "Include": "true"}, {"number": "309", "ReferenceId": "21843312", "FullCitation": "Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312", "Include": "true"}, {"number": "310", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "311", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "312", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "313", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "314", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "315", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "316", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "317", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "318", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "319", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "320", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "321", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "322", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "323", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "324", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "325", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "326", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "327", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "328", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "329", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "330", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "331", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "332", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "333", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "334", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "335", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "336", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "337", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "338", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "339", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "340", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "341", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "342", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "343", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "344", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "345", "ReferenceId": "32322066", "FullCitation": "Touat M, et al. Nature (2020) pmid: 32322066", "Include": "true"}, {"number": "346", "ReferenceId": "27001570", "FullCitation": "Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570", "Include": "true"}, {"number": "347", "ReferenceId": "27683556", "FullCitation": "Johanns TM, et al. Cancer Discov (2016) pmid: 27683556", "Include": "true"}, {"number": "348", "ReferenceId": "30073642", "FullCitation": "Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642", "Include": "true"}, {"number": "349", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "350", "ReferenceId": "32386112", "FullCitation": "Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112", "Include": "true"}, {"number": "351", "ReferenceId": "28912153", "FullCitation": "Johnson A, et al. Oncologist (2017) pmid: 28912153", "Include": "true"}, {"number": "352", "ReferenceId": "26699864", "FullCitation": "Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864", "Include": "true"}, {"number": "353", "ReferenceId": "32164609", "FullCitation": "Wang L, et al. BMC Cancer (2020) pmid: 32164609", "Include": "true"}, {"number": "354", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "355", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "356", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "357", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "358", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "359", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "360", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "361", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "362", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "363", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "364", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "365", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "366", "ReferenceId": "22089350", "FullCitation": "Jha P, et al. Diagn. Mol. Pathol. (2011) pmid: 22089350", "Include": "true"}, {"number": "367", "ReferenceId": "15914282", "FullCitation": "Uno M, et al. Cancer Lett. (2005) pmid: 15914282", "Include": "true"}, {"number": "368", "ReferenceId": "16711514", "FullCitation": "Uno M, et al. Int. J. Biol. Markers () pmid: 16711514", "Include": "true"}, {"number": "369", "ReferenceId": "22844452", "FullCitation": "Lass U, et al. PLoS ONE (2012) pmid: 22844452", "Include": "true"}, {"number": "370", "ReferenceId": "23009112", "FullCitation": "Faria MH, et al. APMIS (2012) pmid: 23009112", "Include": "true"}, {"number": "371", "ReferenceId": "24358143", "FullCitation": "Milinkovic V, et al. PLoS ONE (2013) pmid: 24358143", "Include": "true"}, {"number": "372", "ReferenceId": "23613880", "FullCitation": "Galatro TF, et al. PLoS ONE (2013) pmid: 23613880", "Include": "true"}, {"number": "373", "ReferenceId": "11939587", "FullCitation": "Schmidt MC, et al. J. Neuropathol. Exp. Neurol. (2002) pmid: 11939587", "Include": "true"}, {"number": "374", "ReferenceId": "11550308", "FullCitation": "Nozaki M, et al. Neuro_oncology (1999) pmid: 11550308", "Include": "true"}, {"number": "375", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "376", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "377", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "378", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "379", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "380", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "381", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "382", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "383", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "384", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "385", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "386", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "387", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "388", "ReferenceId": "22446188", "FullCitation": "Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188", "Include": "true"}, {"number": "389", "ReferenceId": "22965953", "FullCitation": "Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953", "Include": "true"}, {"number": "390", "ReferenceId": "26086967", "FullCitation": "Mohell N, et al. Cell Death Dis (2015) pmid: 26086967", "Include": "true"}, {"number": "391", "ReferenceId": "27179933", "FullCitation": "Fransson \u00c5, et al. J Ovarian Res (2016) pmid: 27179933", "Include": "true"}, {"number": "392", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "393", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "394", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "395", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "396", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "397", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "398", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "399", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "400", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "401", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "402", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "403", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "404", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "405", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "406", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "407", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "408", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "409", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "410", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "411", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "412", "ReferenceId": "20399956", "FullCitation": "Grossmann KS, et al. Adv. Cancer Res. (2010) pmid: 20399956", "Include": "true"}, {"number": "413", "ReferenceId": "12717436", "FullCitation": "Tartaglia M, et al. Nat. Genet. (2003) pmid: 12717436", "Include": "true"}, {"number": "414", "ReferenceId": "21575863", "FullCitation": "Bard_Chapeau EA, et al. Cancer Cell (2011) pmid: 21575863", "Include": "true"}, {"number": "415", "ReferenceId": "21934682", "FullCitation": "Sturla LM, et al. Br. J. Cancer (2011) pmid: 21934682", "Include": "true"}, {"number": "416", "ReferenceId": "9791886", "FullCitation": "Sarkisian KA, et al. Vopr. Virusol. () pmid: 9791886", "Include": "true"}, {"number": "417", "ReferenceId": "17053061", "FullCitation": "Chan RJ, et al. Blood (2007) pmid: 17053061", "Include": "true"}, {"number": "418", "ReferenceId": "15644411", "FullCitation": "Chan RJ, et al. Blood (2005) pmid: 15644411", "Include": "true"}, {"number": "419", "ReferenceId": "16358218", "FullCitation": "Tartaglia M, et al. Am. J. Hum. Genet. (2006) pmid: 16358218", "Include": "true"}, {"number": "420", "ReferenceId": "19008228", "FullCitation": "Wang S, et al. J. Biol. Chem. (2009) pmid: 19008228", "Include": "true"}, {"number": "421", "ReferenceId": "15834506", "FullCitation": "Niihori T, et al. J. Hum. Genet. (2005) pmid: 15834506", "Include": "true"}, {"number": "422", "ReferenceId": "15604238", "FullCitation": "Bentires_Alj M, et al. Cancer Res. (2004) pmid: 15604238", "Include": "true"}, {"number": "423", "ReferenceId": "10594032", "FullCitation": "O Reilly AM, et al. Mol. Cell. Biol. (2000) pmid: 10594032", "Include": "true"}, {"number": "424", "ReferenceId": "18378677", "FullCitation": "Eminaga S, et al. J. Biol. Chem. (2008) pmid: 18378677", "Include": "true"}, {"number": "425", "ReferenceId": "22711529", "FullCitation": "Martinelli S, et al. J. Biol. Chem. (2012) pmid: 22711529", "Include": "true"}, {"number": "426", "ReferenceId": "24891296", "FullCitation": "Edwards JJ, et al. Am. J. Med. Genet. A (2014) pmid: 24891296", "Include": "true"}, {"number": "427", "ReferenceId": "24935154", "FullCitation": "Yu ZH, et al. Biochemistry (2014) pmid: 24935154", "Include": "true"}, {"number": "428", "ReferenceId": "18372317", "FullCitation": "Martinelli S, et al. Hum. Mol. Genet. (2008) pmid: 18372317", "Include": "true"}, {"number": "429", "ReferenceId": "27030275", "FullCitation": "LaRochelle JR, et al. Biochemistry (2016) pmid: 27030275", "Include": "true"}, {"number": "430", "ReferenceId": "30375388", "FullCitation": "LaRochelle JR, et al. Nat Commun (2018) pmid: 30375388", "Include": "true"}, {"number": "431", "ReferenceId": "15710330", "FullCitation": "Mohi MG, et al. Cancer Cell (2005) pmid: 15710330", "Include": "true"}, {"number": "432", "ReferenceId": "15761018", "FullCitation": "Schubbert S, et al. Blood (2005) pmid: 15761018", "Include": "true"}, {"number": "433", "ReferenceId": "19179468", "FullCitation": "Chan G, et al. Blood (2009) pmid: 19179468", "Include": "true"}, {"number": "434", "ReferenceId": "20651068", "FullCitation": "Xu D, et al. Blood (2010) pmid: 20651068", "Include": "true"}, {"number": "435", "ReferenceId": "23817572", "FullCitation": "Jones DT, et al. Nat. Genet. (2013) pmid: 23817572", "Include": "true"}, {"number": "436", "ReferenceId": "19621452", "FullCitation": "Schuettpelz LG, et al. Pediatr Blood Cancer (2009) pmid: 19621452", "Include": "true"}, {"number": "437", "ReferenceId": "27579614", "FullCitation": "Ferguson SD, et al. Oncotarget (2016) pmid: 27579614", "Include": "true"}, {"number": "438", "ReferenceId": "21393858", "FullCitation": "Liu KW, et al. J. Clin. Invest. (2011) pmid: 21393858", "Include": "true"}, {"number": "439", "ReferenceId": "21996738", "FullCitation": "Feng H, et al. Oncogene (2012) pmid: 21996738", "Include": "true"}, {"number": "440", "ReferenceId": "18421299", "FullCitation": "Zhou XD, et al. Cell Death Differ. (2008) pmid: 18421299", "Include": "true"}, {"number": "441", "ReferenceId": "29097496", "FullCitation": "Voruz S, et al. Haematologica (2018) pmid: 29097496", "Include": "true"}, {"number": "442", "ReferenceId": "29884903", "FullCitation": "Tasian SK, et al. Leukemia (2019) pmid: 29884903", "Include": "true"}, {"number": "443", "ReferenceId": "16166557", "FullCitation": "Krenz M, et al. Circ. Res. (2005) pmid: 16166557", "Include": "true"}, {"number": "444", "ReferenceId": "19706403", "FullCitation": "Nakamura T, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19706403", "Include": "true"}, {"number": "445", "ReferenceId": "20578946", "FullCitation": "Brasil AS, et al. Genet Test Mol Biomarkers (2010) pmid: 20578946", "Include": "true"}, {"number": "446", "ReferenceId": "20029231", "FullCitation": "Horm. Res. (2009) pmid: 20029231", "Include": "true"}, {"number": "447", "ReferenceId": "16518851", "FullCitation": "Chen Y, et al. Genes Chromosomes Cancer (2006) pmid: 16518851", "Include": "true"}, {"number": "448", "ReferenceId": "19077116", "FullCitation": "Pierpont EI, et al. Genes Brain Behav. (2009) pmid: 19077116", "Include": "true"}, {"number": "449", "ReferenceId": "24754368", "FullCitation": "Mathur D, et al. Fetal Pediatr Pathol (2014) pmid: 24754368", "Include": "true"}, {"number": "450", "ReferenceId": "16118227", "FullCitation": "Sun XJ, et al. J. Biol. Chem. (2005) pmid: 16118227", "Include": "true"}, {"number": "451", "ReferenceId": "9700202", "FullCitation": "Faber PW, et al. Hum. Mol. Genet. (1998) pmid: 9700202", "Include": "true"}, {"number": "452", "ReferenceId": "19698110", "FullCitation": "Al Sarakbi W, et al. BMC Cancer (2009) pmid: 19698110", "Include": "true"}, {"number": "453", "ReferenceId": "27282254", "FullCitation": "Parker H, et al. Leukemia (2016) pmid: 27282254", "Include": "true"}, {"number": "454", "ReferenceId": "22237106", "FullCitation": "Zhang J, et al. Nature (2012) pmid: 22237106", "Include": "true"}, {"number": "455", "ReferenceId": "28122867", "FullCitation": "McKinney M, et al. Cancer Discov (2017) pmid: 28122867", "Include": "true"}, {"number": "456", "ReferenceId": "28424246", "FullCitation": "Moffitt AB, et al. J. Exp. Med. (2017) pmid: 28424246", "Include": "true"}, {"number": "457", "ReferenceId": "24509477", "FullCitation": "Zhu X, et al. Nat. Genet. (2014) pmid: 24509477", "Include": "true"}, {"number": "458", "ReferenceId": "27174990", "FullCitation": "Lu C, et al. Science (2016) pmid: 27174990", "Include": "true"}, {"number": "459", "ReferenceId": "21248752", "FullCitation": "Varela I, et al. Nature (2011) pmid: 21248752", "Include": "true"}, {"number": "460", "ReferenceId": "29522714", "FullCitation": "Chen Z, et al. Biochem Biophys Res Commun (2018) pmid: 29522714", "Include": "true"}, {"number": "461", "ReferenceId": "32202636", "FullCitation": "Chen BY, et al. Blood (2020) pmid: 32202636", "Include": "true"}, {"number": "462", "ReferenceId": "21566061", "FullCitation": "Ha K, et al. Mol. Cancer Ther. (2011) pmid: 21566061", "Include": "true"}, {"number": "463", "ReferenceId": "19034564", "FullCitation": "Liang Y, et al. World J Surg (2009) pmid: 19034564", "Include": "true"}, {"number": "464", "ReferenceId": "18519640", "FullCitation": "Mordes DA, et al. Genes Dev. (2008) pmid: 18519640", "Include": "true"}, {"number": "465", "ReferenceId": "19969004", "FullCitation": "Wang H, et al. Life Sci. (2010) pmid: 19969004", "Include": "true"}, {"number": "466", "ReferenceId": "22276931", "FullCitation": "Levin VA, et al. Proteome Sci (2012) pmid: 22276931", "Include": "true"}, {"number": "467", "ReferenceId": "21730979", "FullCitation": "Peasland A, et al. Br. J. Cancer (2011) pmid: 21730979", "Include": "true"}, {"number": "468", "ReferenceId": "16912188", "FullCitation": "McCabe N, et al. Cancer Res. (2006) pmid: 16912188", "Include": "true"}, {"number": "469", "ReferenceId": "19570909", "FullCitation": "Jardim MJ, et al. Mol. Biol. Cell (2009) pmid: 19570909", "Include": "true"}, {"number": "470", "ReferenceId": "1937255", "FullCitation": "Harefuah (1991) pmid: 1937255", "Include": "true"}, {"number": "471", "ReferenceId": "21258400", "FullCitation": "Sangster_Guity N, et al. Oncogene (2011) pmid: 21258400", "Include": "true"}, {"number": "472", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "473", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "474", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "475", "ReferenceId": "15331927", "FullCitation": "Martinez R, et al. Oncology (2004) pmid: 15331927", "Include": "true"}, {"number": "476", "ReferenceId": "15672285", "FullCitation": "Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285", "Include": "true"}, {"number": "477", "ReferenceId": "17498554", "FullCitation": "Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554", "Include": "true"}, {"number": "478", "ReferenceId": "12908754", "FullCitation": "Szybka M, et al. Clin. Neuropathol. () pmid: 12908754", "Include": "true"}, {"number": "479", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "480", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "481", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "482", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "483", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "484", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "485", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "486", "ReferenceId": "19659756", "FullCitation": "Lynch HT, et al. Clin. Genet. (2009) pmid: 19659756", "Include": "true"}, {"number": "487", "ReferenceId": "22714864", "FullCitation": "Pande M, et al. Fam. Cancer (2012) pmid: 22714864", "Include": "true"}, {"number": "488", "ReferenceId": "17920897", "FullCitation": "Kastrinos F, et al. Semin. Oncol. (2007) pmid: 17920897", "Include": "true"}, {"number": "489", "ReferenceId": "19466295", "FullCitation": "Silva FC, et al. Sao Paulo Med J (2009) pmid: 19466295", "Include": "true"}, {"number": "490", "ReferenceId": "24978665", "FullCitation": "Sehgal R, et al. Genes (Basel) (2014) pmid: 24978665", "Include": "true"}, {"number": "491", "ReferenceId": "16136383", "FullCitation": "Fam. Cancer (2005) pmid: 16136383", "Include": "true"}, {"number": "492", "ReferenceId": "28339824", "FullCitation": "Banerjee A, et al. Neuro_oncology (2017) pmid: 28339824", "Include": "true"}, {"number": "493", "ReferenceId": "24567366", "FullCitation": "Gupta A, et al. Ann. Oncol. (2014) pmid: 24567366", "Include": "true"}, {"number": "494", "ReferenceId": "23735514", "FullCitation": "Robert C, et al. Lancet Oncol. (2013) pmid: 23735514", "Include": "true"}, {"number": "495", "ReferenceId": "22048237", "FullCitation": "Kirkwood JM, et al. Clin. Cancer Res. (2012) pmid: 22048237", "Include": "true"}, {"number": "496", "ReferenceId": "20179232", "FullCitation": "Banerji U, et al. Clin. Cancer Res. (2010) pmid: 20179232", "Include": "true"}, {"number": "497", "ReferenceId": "22293660", "FullCitation": "Boers_Sonderen MJ, et al. Anticancer Drugs (2012) pmid: 22293660", "Include": "true"}, {"number": "498", "ReferenceId": "25667274", "FullCitation": "Lopez_Chavez A, et al. J. Clin. Oncol. (2015) pmid: 25667274", "Include": "true"}, {"number": "499", "ReferenceId": "20802351", "FullCitation": "Hainsworth JD, et al. J Thorac Oncol (2010) pmid: 20802351", "Include": "true"}, {"number": "500", "ReferenceId": "25887099", "FullCitation": "Coleman RL, et al. Gynecol. Oncol. (2015) pmid: 25887099", "Include": "true"}, {"number": "501", "ReferenceId": "26666244", "FullCitation": "Deming DA, et al. Invest New Drugs (2016) pmid: 26666244", "Include": "true"}, {"number": "502", "ReferenceId": "30042150", "FullCitation": "Krishnamurthy A, et al. Cancer Res. (2018) pmid: 30042150", "Include": "true"}, {"number": "503", "ReferenceId": "28424891", "FullCitation": "Infante JR, et al. Invest New Drugs (2017) pmid: 28424891", "Include": "true"}, {"number": "504", "ReferenceId": "28264648", "FullCitation": "LoRusso PM, et al. BMC Cancer (2017) pmid: 28264648", "Include": "true"}, {"number": "505", "ReferenceId": "25516890", "FullCitation": "Tolcher AW, et al. Clin. Cancer Res. (2015) pmid: 25516890", "Include": "true"}, {"number": "506", "ReferenceId": "25268371", "FullCitation": "Wilky BA, et al. Br. J. Cancer (2015) pmid: 25268371", "Include": "true"}, {"number": "507", "ReferenceId": "28009226", "FullCitation": "Miller C, et al. J Neurosurg Pediatr (2017) pmid: 28009226", "Include": "true"}, {"number": "508", "ReferenceId": "27810072", "FullCitation": "Yde CW, et al. Cancer Genet (2016) pmid: 27810072", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_09_22 14:47:28", "OpName": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "832x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "25 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "_4 pca_score"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BRAIN", "disease_ontology": "Brain glioblastoma (GBM)", "flowcell_analysis": "2000017641", "gender": "male", "pathology_diagnosis": "Glioblastoma", "percent_tumor_nuclei": "30", "pipeline_version": "v3.7.0", "purity_assessment": "21.5", "specimen": "ORD_1188306_01*US1148014.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1188306_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Brain", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "829.21", "name": "SQ_US1148014.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.0204", "cds_effect": "1510A>G", "depth": "685", "equivocal": "false", "functional_effect": "missense", "gene": "PTPN11", "percent_reads": "2.04", "position": "chr12:112926890", "protein_effect": "M504V", "status": "known", "strand": "+", "subclonal": "true", "transcript": "NM_002834", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2559", "cds_effect": "1582_1G>T", "depth": "715", "equivocal": "false", "functional_effect": "splice", "gene": "SYK", "percent_reads": "25.59", "position": "chr9:93650030", "protein_effect": "splice site 1582_1G>T", "status": "unknown", "strand": "+", "transcript": "NM_003177", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.3502", "cds_effect": "2911G>A", "depth": "614", "equivocal": "false", "functional_effect": "missense", "gene": "RPTOR", "percent_reads": "35.02", "position": "chr17:78899272", "protein_effect": "V971I", "status": "unknown", "strand": "+", "transcript": "NM_020761", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2632", "cds_effect": "763C>T", "depth": "893", "equivocal": "false", "functional_effect": "nonsense", "gene": "EGFR", "percent_reads": "26.32", "position": "chr7:55221719", "protein_effect": "R255*", "status": "unknown", "strand": "+", "transcript": "NM_005228", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2754", "cds_effect": "328C>T", "depth": "679", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "27.54", "position": "chr17:7579359", "protein_effect": "R110C", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.0114", "cds_effect": "697C>T", "depth": "1143", "equivocal": "false", "functional_effect": "nonsense", "gene": "PTEN", "percent_reads": "1.14", "position": "chr10:89717672", "protein_effect": "R233*", "status": "known", "strand": "+", "subclonal": "true", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2607", "cds_effect": "1385C>T", "depth": "840", "equivocal": "false", "functional_effect": "missense", "gene": "TNFAIP3", "percent_reads": "26.07", "position": "chr6:138199967", "protein_effect": "P462L", "status": "unknown", "strand": "+", "transcript": "NM_006290", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2963", "cds_effect": "5516G>A", "depth": "594", "equivocal": "false", "functional_effect": "missense", "gene": "POLE", "percent_reads": "29.63", "position": "chr12:133215747", "protein_effect": "R1839H", "status": "unknown", "strand": "_", "transcript": "NM_006231", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.5735", "cds_effect": "3043G>A", "depth": "490", "equivocal": "false", "functional_effect": "missense", "gene": "BCORL1", "percent_reads": "57.35", "position": "chrX:129149791", "protein_effect": "D1015N", "status": "unknown", "strand": "+", "transcript": "NM_021946", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2832", "cds_effect": "1577C>T", "depth": "632", "equivocal": "false", "functional_effect": "missense", "gene": "AXIN1", "percent_reads": "28.32", "position": "chr16:347929", "protein_effect": "A526V", "status": "unknown", "strand": "_", "transcript": "NM_003502", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.1608", "cds_effect": "4291G>A", "depth": "659", "equivocal": "false", "functional_effect": "missense", "gene": "MTOR", "percent_reads": "16.08", "position": "chr1:11227537", "protein_effect": "G1431R", "status": "unknown", "strand": "_", "transcript": "NM_004958", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2204", "cds_effect": "4313G>A", "depth": "658", "equivocal": "false", "functional_effect": "missense", "gene": "TSC2", "percent_reads": "22.04", "position": "chr16:2134536", "protein_effect": "R1438Q", "status": "known", "strand": "+", "transcript": "NM_000548", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.1453", "cds_effect": "1018G>A", "depth": "709", "equivocal": "false", "functional_effect": "missense", "gene": "ZNF703", "percent_reads": "14.53", "position": "chr8:37555437", "protein_effect": "G340S", "status": "unknown", "strand": "+", "transcript": "NM_025069", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2445", "cds_effect": "6072_6073insA", "depth": "548", "equivocal": "false", "functional_effect": "frameshift", "gene": "ATR", "percent_reads": "24.45", "position": "chr3:142211979", "protein_effect": "Y2025fs*2", "status": "likely", "strand": "_", "transcript": "NM_001184", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2", "cds_effect": "1492C>T", "depth": "660", "equivocal": "false", "functional_effect": "missense", "gene": "PTPN11", "percent_reads": "20.0", "position": "chr12:112926872", "protein_effect": "R498W", "status": "known", "strand": "+", "transcript": "NM_002834", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2619", "cds_effect": "2098C>T", "depth": "649", "equivocal": "false", "functional_effect": "missense", "gene": "BAP1", "percent_reads": "26.19", "position": "chr3:52436396", "protein_effect": "R700W", "status": "unknown", "strand": "_", "transcript": "NM_004656", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2467", "cds_effect": "172C>T", "depth": "758", "equivocal": "false", "functional_effect": "nonsense", "gene": "CDKN2A", "percent_reads": "24.67", "position": "chr9:21971186", "protein_effect": "R58*", "status": "known", "strand": "_", "transcript": "NM_000077", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2839", "cds_effect": "1183C>T", "depth": "1078", "equivocal": "false", "functional_effect": "missense", "gene": "BARD1", "percent_reads": "28.39", "position": "chr2:215645415", "protein_effect": "P395S", "status": "unknown", "strand": "_", "transcript": "NM_000465", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.4895", "cds_effect": "1685C>T", "depth": "666", "equivocal": "false", "functional_effect": "missense", "gene": "TBX3", "percent_reads": "48.95", "position": "chr12:115112055", "protein_effect": "A562V", "status": "unknown", "strand": "_", "transcript": "NM_016569", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.258", "cds_effect": "389G>A", "depth": "655", "equivocal": "false", "functional_effect": "missense", "gene": "PRKCI", "percent_reads": "25.8", "position": "chr3:169985727", "protein_effect": "R130H", "status": "unknown", "strand": "+", "transcript": "NM_002740", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.1812", "cds_effect": "1976delG", "depth": "883", "equivocal": "false", "functional_effect": "frameshift", "gene": "RNF43", "percent_reads": "18.12", "position": "chr17:56435160", "protein_effect": "G659fs*41", "status": "known", "strand": "_", "transcript": "NM_017763", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.5836", "cds_effect": "1979G>A", "depth": "305", "equivocal": "false", "functional_effect": "missense", "gene": "RBM10", "percent_reads": "58.36", "position": "chrX:47044482", "protein_effect": "R660H", "status": "unknown", "strand": "+", "transcript": "NM_005676", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.4132", "cds_effect": "1019_1020delCT", "depth": "968", "equivocal": "false", "functional_effect": "frameshift", "gene": "NF1", "percent_reads": "41.32", "position": "chr17:29527569", "protein_effect": "S340fs*12", "status": "likely", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.0217", "cds_effect": "40G>A", "depth": "737", "equivocal": "false", "functional_effect": "missense", "gene": "KRAS", "percent_reads": "2.17", "position": "chr12:25398279", "protein_effect": "V14I", "status": "known", "strand": "_", "subclonal": "true", "transcript": "NM_004985", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.3072", "cds_effect": "112C>T", "depth": "726", "equivocal": "false", "functional_effect": "missense", "gene": "PAX5", "percent_reads": "30.72", "position": "chr9:37020733", "protein_effect": "R38C", "status": "unknown", "strand": "_", "transcript": "NM_016734", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.1468", "cds_effect": "4234A>G", "depth": "824", "equivocal": "false", "functional_effect": "missense", "gene": "NF1", "percent_reads": "14.68", "position": "chr17:29585422", "protein_effect": "R1412G", "status": "unknown", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.279", "cds_effect": "490G>T", "depth": "921", "equivocal": "false", "functional_effect": "missense", "gene": "MSH2", "percent_reads": "27.9", "position": "chr2:47637356", "protein_effect": "G164W", "status": "unknown", "strand": "+", "transcript": "NM_000251", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.264", "cds_effect": "4912_4913insA", "depth": "659", "equivocal": "false", "functional_effect": "frameshift", "gene": "SETD2", "percent_reads": "26.4", "position": "chr3:47144840", "protein_effect": "W1640fs*26", "status": "likely", "strand": "_", "transcript": "NM_014159", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.5084", "cds_effect": "1764C>G", "depth": "417", "equivocal": "false", "functional_effect": "missense", "gene": "DOT1L", "percent_reads": "50.84", "position": "chr19:2213952", "protein_effect": "D588E", "status": "unknown", "strand": "+", "transcript": "NM_032482", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2424", "cds_effect": "2540C>T", "depth": "891", "equivocal": "false", "functional_effect": "missense", "gene": "PDGFRA", "percent_reads": "24.24", "position": "chr4:55152108", "protein_effect": "S847L", "status": "known", "strand": "+", "transcript": "NM_006206", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.1838", "cds_effect": "331A>G", "depth": "751", "equivocal": "false", "functional_effect": "missense", "gene": "CALR", "percent_reads": "18.38", "position": "chr19:13050379", "protein_effect": "K111E", "status": "unknown", "strand": "+", "transcript": "NM_004343", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.1538", "cds_effect": "2867G>A", "depth": "904", "equivocal": "false", "functional_effect": "missense", "gene": "KIT", "percent_reads": "15.38", "position": "chr4:55604659", "protein_effect": "R956Q", "status": "unknown", "strand": "+", "transcript": "NM_000222", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.163", "cds_effect": "1103C>T", "depth": "638", "equivocal": "false", "functional_effect": "missense", "gene": "RPTOR", "percent_reads": "16.3", "position": "chr17:78796990", "protein_effect": "P368L", "status": "unknown", "strand": "+", "transcript": "NM_020761", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.4922", "cds_effect": "665G>A", "depth": "451", "equivocal": "false", "functional_effect": "missense", "gene": "JAK3", "percent_reads": "49.22", "position": "chr19:17953321", "protein_effect": "R222H", "status": "unknown", "strand": "_", "transcript": "NM_000215", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2324", "cds_effect": "1503C>G", "depth": "641", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR1", "percent_reads": "23.24", "position": "chr8:38275437", "protein_effect": "D501E", "status": "unknown", "strand": "_", "transcript": "NM_023110", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2177", "cds_effect": "2561_2563delAGA", "depth": "827", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "MSH6", "percent_reads": "21.77", "position": "chr2:48027682", "protein_effect": "K854del", "status": "unknown", "strand": "+", "transcript": "NM_000179", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2865", "cds_effect": "524G>A", "depth": "775", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "28.65", "position": "chr17:7578406", "protein_effect": "R175H", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2632", "cds_effect": "499G>A", "depth": "570", "equivocal": "false", "functional_effect": "missense", "gene": "MAP2K2", "percent_reads": "26.32", "position": "chr19:4102403", "protein_effect": "E167K", "status": "unknown", "strand": "_", "transcript": "NM_030662", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}, {"allele_fraction": "0.2674", "cds_effect": "1283C>T", "depth": "774", "equivocal": "false", "functional_effect": "missense", "gene": "ERCC4", "percent_reads": "26.74", "position": "chr16:14029072", "protein_effect": "A428V", "status": "known", "strand": "+", "transcript": "NM_005236", "dna_evidence": {"sample": "SQ_US1148014.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "unknown"}, "tumor_mutation_burden": {"score": "25.22", "status": "high", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}